



HAL
open science

Synthesis and antiplasmodial activity of novel Fosmidomycin derivatives and conjugates with Artemisinin and Aminochoquinoline

Despina Palla, Antonia Antoniou, Michel Baltas, Christophe Menendez, Philippe Grellier, Mouray Elisabeth, Constantinos Athanassopoulos

► **To cite this version:**

Despina Palla, Antonia Antoniou, Michel Baltas, Christophe Menendez, Philippe Grellier, et al.. Synthesis and antiplasmodial activity of novel Fosmidomycin derivatives and conjugates with Artemisinin and Aminochoquinoline. *Molecules*, 2020, 25 (20), pp.4858. 10.3390/molecules25204858 . hal-02967532

HAL Id: hal-02967532

<https://hal.science/hal-02967532v1>



Submitted on 26 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

Synthesis and Antiplasmodial Activity of Novel Fosmidomycin Derivatives and Conjugates with Artemisinin and Aminochoquinoline

Despina Palla ¹, Antonia I. Antoniou ¹, Michel Baltas ^{2,3}, Christophe Menendez ^{2,3},
Philippe Grellier ⁴ , Elisabeth Mouray ⁴ and Constantinos M. Athanassopoulos ^{1,*} 

¹ Synthetic Organic Chemistry Laboratory, Department of Chemistry, University of Patras, GR-26504 Patras, Greece; despina.pal.5@gmail.com (D.P.); tonadoniou@upatras.gr (A.I.A.)

² LSPCMIB, UMR-CNRS 5068, Université Paul Sabatier-Toulouse III, CEDEX 9, 31062 Toulouse, France; baltas@chimie.ups-tlse.fr or michel.baltas@lcc-toulouse.fr (M.B.); menendez@chimie.ups-tlse.fr (C.M.)

³ CNRS, LCC (Laboratoire de Chimie, de Coordination), Université de Toulouse, UPS, INPT, 205 Route de Narbonne, BP 44099, CEDEX 4 F-31077 Toulouse, France

⁴ MCAM, UMR 7245, Muséum National d'Histoire Naturelle, CNRS, CP52, 63 rue Buffon, 75005 Paris, France; grellier@mnhn.fr (P.G.); mouray@mnhn.fr (E.M.)

* Correspondence: kath@chemistry.upatras.gr; Tel.: +30-2610-997909

Academic Editors: Halina Ekiert and Agnieszka Szopa

Received: 26 September 2020; Accepted: 16 October 2020; Published: 21 October 2020



Abstract: Malaria, despite many efforts, remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by *Plasmodium falciparum*. The antibiotic fosmidomycin (FSM) is also known for its antimalarial activity by targeting the non-mevalonate isoprenoid synthesis pathway, which is essential for the malaria parasites but is absent in mammals. In this study, we synthesized and evaluated against the chloroquine-resistant *P. falciparum* FcB1/Colombia strain, a series of FSM analogs, derivatives, and conjugates with other antimalarial agents, such as artemisinin (ART) and aminochoquinoline (ACQ). The biological evaluation revealed four new compounds with higher antimalarial activity than FSM: two FSM-ACQ derivatives and two FSM-ART conjugates, with 3.5–5.4 and 41.5–23.1 times more potent activities than FSM, respectively.

Keywords: fosmidomycin; chloroquine; artemisinin; hybrid; conjugates; antimalarial activity

1. Introduction

Despite worldwide efforts, malaria remains among the most dangerous infectious diseases. Malaria incidence has decreased significantly since 2010, but, unfortunately, after 2014, the number of malaria cases is increasing again, according to the World Health Organization [1]. The main reason is the elevated resistance to artemisinin combination therapy (ACT) [2]. In that respect, there is an urgent need for antimalarial agents with a novel mechanism of action (MOA).

During the last decade of the 20th century, the discovery of the non-mevalonate isoprenoid biosynthesis pathway as an essential target raised hope for potential therapeutic opportunities [3]. The pathway is proved to be essential for malaria parasites, while it is absent in mammalian hosts who generate isoprenoids exclusively via the mevalonate pathway [4,5]. The enzymes of the non-mevalonate pathway are located in the apicoplast organelle of malaria parasites, which only host small numbers of proteins, thus becoming attractive drug targets [6–8]. In this respect, the seminal work of Jomaa et al. [9] set the basis of an intense research work on compounds targeting the non-mevalonate pathway of the *Plasmodium*. These authors reported in 1999 that the antibiotic fosmidomycin (FSM, **1**, **Figure 1**) inhibits the IspC (see **Figure 1**), which catalyzes the first committed step of the non-mevalonate pathway and is believed to be rate limiting. FSM, which was initially isolated from *Streptomyces lavendulae* [10,11],

is a phosphonate structural analogue of the IspC substrate DOXP (**4**), which furthermore bears a hydroxamic acid moiety in replacement of the alpha hydroxy ketone of **4** and thus is not subject to hydrolysis by cellular phosphatases [12]. FSM may act as a transition state intermediate, with the hydroxamic acid group chelating the metal ion and the phosphono moiety resembling the phosphate group of **4** [13]. FSM was first developed as an antibacterial agent, but due to its less than ideal pharmacokinetics [10,11,14], it was abandoned and later repositioned as a potential antimalarial, inhibiting a new different target compared to artemisinin (ART). The shortcomings of FSM have prompted attempts by several research groups to improve its activity by performing several chemical modifications, suitable for structure–activity relationship studies [15–22]. One of the most studied FSM's analogues is FR900098 (**2**), a phosphonic acid antibiotic, where the formyl group of FSM is replaced by an acetyl one. Although it is structurally very close to FSM, it is about twice as active as FSM *in vitro* and in a mouse model [9,23,24].




Figure 1. Structures of FSM, FR900098, and various FSM derivatives.

In brief, structural modifications of FSM have focused on four main areas: (i) replacement of the phosphonate motif by (bio)isosteres (**3**, **7**, **8**, **11**), synthesis of phosphonate prodrugs (**6**, **9**) [25]; (ii) replacement or modification of the hydroxamate moiety that chelates the catalytically essential divalent cation, e.g., compounds **10–14** [26,27]; (iii) modulation of the aliphatic linker between the anionic anchor group and the chelating head group, e.g., compounds **14–15** [28]; and (iv) modification of the aliphatic chain by introduction of (typically aromatic) substituents, e.g., compounds **15** [22]. As an example, FR900098-prodrugs, where an acetyl group replaced the formyl one of the FSM, displayed improved *in vitro* and enhanced *in vivo* activity [9]. Furthermore, lipophilic phosphonate prodrug derivatives of FSM have previously been reported to display significantly enhanced antiplasmodial [29] and antimicrobial activities [30].

Recent studies have shown that the combination of two antimalarial drugs with different molecular targets in one single entity either as a hybrid or a conjugate proved to be more efficient against diseases,

such as malaria and cancer [31]. Hybrid molecules are rather promising since they have less possibilities of developing drug resistance [32].

In this work, a synthesis and antiplasmodial evaluation along with the cytotoxicity of three focused families of compounds possessing the propyl phosphonate frame (ester or acid form) of FSM are reported. The first family contains five compounds: FSM, FR900098, and their phosphonate diesters (**16**, **17**), along with a dimeric form of FSM (**18**). The second family was constructed by attaching active antimalarial pharmacophores like ACQ (**19–20**) [33] or ART (**21–23**) [34,35] next to the carbonyl group of the hydroxamate thus preparing five new compounds (hybrids or conjugates). The third family (10 compounds, **26–33**) possesses various amines connected to the hydroxamic function. For the last two compounds (**34**, **35**), the hydroxamate moiety was replaced by *o*-phenylenediamine, thus changing the nature of the groups that might intervene in the chelation process (Figure 2).





Figure 2. Structures of the FSM derivatives synthesized in this work (16–35).

2. Results and Discussion

2.1. Synthesis of the Key Intermediate 39, FSM, FR9000098, and Dimer 18

The first family includes the known compounds FSM and FR9000098 and their corresponding esters (compounds **16** and **17**, Scheme 1), along with the tetraethylphosphonate dimer **18**. Synthesis of FSM and FR900098 was conducted as reported in the literature by Suresh et al. [36] and Uh et al. [37]. *tert*-Butyl *N*-(benzyloxy)carbamate **36** and the bromophosphonic diester **37** were synthesized in an 89%

and 50% total yield, respectively, according to literature procedures [21,25]. Coupling of compounds **36** and **37** followed by TFA-mediated cleavage of the Boc protective group, yielded the key-intermediate synthon **39** in a 94% yield (two steps).



Scheme 1. Synthesis of key intermediate **39**, FSM and FR900098 monosodium salts, and FSM dimer **18**; Reagents and conditions: (a) NaH, NaI, DMF, rt to 60 °C, 17 h, 96%; (b) TFA, CH₂Cl₂, 0 °C to rt, 1.5 h, 98%; (c) for **40**: HCOOH, (CH₃CO)₂O₂, -5 °C to rt, overnight, 91% and for **41**: CH₃COCl, Et₃N, DCM, 0 °C to rt, overnight, 98%; (d) H₂, 10% Pd/C, MeOH, rt (3 h, 91% for **16** and 4 h, 99% for **17**); (e) (i) TMSBr, CH₂Cl₂, 0 °C to rt, 8 h (ii) 6N aq. NaOH/MeOH (87% for FSM and 90% for FR900098 over 2 steps); (f) succinic anhydride, DIPEA, DMAP, THF, rt, 3 h, 88%; (g) **39**, HBTU, Et₃N, CHCl₃, rt, 3.5 h, 61% (h) H₂, 10% Pd/C, MeOH, rt, 3 h, 50%.


FSM was obtained in three steps and 72% total yield through formylation of the secondary amine of compound **39**, hydrogenolysis of the benzyl protective group affording compound **16**, and deprotection of the ethyl ester functions followed by a basic work-up.

Compounds **17** and FR900098 were obtained through a similar sequence of reactions involving acetylation of **39**, hydrogenolysis, and ethyl ester groups' elimination. This sequence afforded better yields concerning acetylation and hydrogenolysis; thus compound **17** and FR900098 were obtained in a 68% and 83% yield, respectively. Based on this procedure, the FSM dimer **18** was synthesized (Scheme 1) by introducing a succinic acid spacer between the two fragments. Thus, compound **39** was allowed to react with succinic anhydride in the presence of a catalytic amount of 4-(dimethylamino)pyridine (DMAP), providing the acid **42** in an 88% yield. Then, coupling of **42** with the amine **39** was performed using the system HBTU/Et₃N in chloroform to give the protected fosmidomycin dimer **43** in a 61% yield. Cleavage of the benzyl groups by cat. hydrogenolysis led to the tetraethyl phosphonate **18** in moderate yield (50%, Scheme 1).


2.2. Synthesis of FSM-ACQ **19–20** and FSM-ART Conjugates **21–23**

Concerning the second family of compounds, namely the FSM conjugates, the FSM core is attached through a linker to either 4-amino-7-chloro-quinoline (ACQ) or artemisinin frames. In this respect, five compounds were synthesized, two of them bearing the ACQ and three the ART moiety (compounds **19–20** (Scheme 2) and **21–23**, respectively, Schemes 3 and 4). For the FSM-ACQ conjugates, two different ACQ amine derivatives (**44** and **45**), bearing a piperazine or an ethylenediamine linker attached in position 4 of the 4,7-dichloroquinoline [38], were prepared. While coupling of *O*-benzyl compound **42** with the piperazino chloroquinoline **44** worked well, the following cleavage of the benzyl group proved to be harsh, affording a mixture of compounds, where hydrogenolysis of the quinoline

group was also observed. By reversing the sequence of reactions, thus first performing hydrogenolysis and then coupling of the hydroxamic acid **47** with piperazine **44**, the desired hybrid **19** was obtained in a 58% yield over two steps.




Scheme 2. Synthesis FSM-ACQ conjugates **19** and **20**; Reagents and conditions: (a) **44**, HBTU, Et₃N, CHCl₃, rt, 3.5 h, 61% (b) H₂, 10% Pd/C, MeOH, rt, 3 h; (c) H₂, 10% Pd/C, MeOH, rt, 5 h, 97%; (d) **44**, HBTU, DIPEA, CHCl₃, rt, 2 h, 60%; (e) Boc₂O, Et₃N, DMAP, CH₂Cl₂, rt, overnight, 30%; (f) **45**, HBTU, Et₃N, CHCl₃, DMF, 4 h, 50%; (g) TFA, CH₂Cl₂, overnight, 60%.



Scheme 3. Synthesis of FSM-ART conjugate **21**; Reagents and conditions: (a) **39**, HBTU, Et₃N, CH₂Cl₂, overnight, 50%; (b) H₂, 10% Pd/C, MeOH, rt, 4 h, 90%.

For the second hybrid, possessing an ethylene diamine linker, this sequence of reactions could not be applied. A complex mixture of compounds was obtained that was difficult to purify. In this respect, the Boc group was used as alternative protection for the hydroxamic function; treatment of **47** with the system Boc₂O/Et₃N/DMAP afforded acid **48** and then followed a coupling reaction with the primary amino group of compound **45** to give the desired compound **49** in a 50% yield, after FCC purification. Boc-deprotection, by TFA-mediated acidolysis, yielded the FSM-ACQ hybrid **20** in a 60% yield.



Scheme 4. Synthesis of the FSM-ART conjugates 22–23 and FSM derivatives 24–25; Reagents and conditions: (a) **42**, HBTU, DIPEA, CHCl_3 , rt, 7 h (72% for **54** and 96% for **55**) (b) TFA, TFE, CH_2Cl_2 , 5 h (90% for **56** and 98% for **57**); (c) H_2 , 10% Pd/C, MeOH, rt, 6.5 h (91% for **24** and 95% for **25**); (d) $2 \times$ **50**, HBTU, DIPEA, CH_2Cl_2 , overnight, 50%; (e) H_2 , 10% Pd/C, MeOH, rt, 4 h (60% for **22** and 80% for **23**).


For FSM-ART conjugates, one artemisinin fragment was first introduced through the acid derivative **50** (Scheme 3), which was prepared as previously described [35]. Reaction of compound **50** with benzyloxyamine **39** under peptide coupling conditions afforded derivative **51**, which upon hydrogenolysis reaction led to FSM-ART hybrid **21** in a 45% yield over 2 steps, after FCC purification.

Moreover, based on our recent work, where hybrids possessing two artemisinin moieties linked with polyamine spacers, such as spermidine or homospermidine, present very good activities against *Plasmodium falciparum* [28], compounds **22** and **2**, possessing a FSM moiety attached through a spermidine or homospermidine linkers to two artemisinin moieties, were synthesized. Protected spermidine and homospermidine derivatives **52** and **53**, respectively, were prepared according to the procedure described in our previous work [35]. Reaction of **52** and **53** with the acid **42** under different and optimal coupling conditions afforded compounds **54** and **55** in 72% and 96% yields, respectively. One-pot deprotection of both benzyl and trityl groups under catalytic hydrogenation conditions unfortunately afforded a mixture of compounds. We thus proceeded in two steps: first with TFA-mediated acidolysis of the trityl groups, followed by hydrogenation for the benzyl group cleavage. The two-step procedure afforded the valuable intermediates **24** and **25** in 91% and 95% yields, respectively (Scheme 4).

Attempts to couple compounds **24** or **25** with the artemisinin acid derivative **50** as for the ACQ derivatives failed to proceed in a clean manner; a mixture of derivatives bearing two and three artemisinin moieties appeared in the mass spectrum, also indicating coupling on the N-OH function. So, precursors **56** and **57** were allowed to react with artemisinin acid **50** (Scheme 4) using HBTU as the coupling agent, in order to afford the benzylated derivatives **58** and **59** in a 50% yield. The latter were then hydrogenated, leading to the final FSM-ART hybrids **22** and **23** in 60% and 80% yields, respectively, after flash column chromatography (FCC) purification.

2.3. Synthesis of FSM Derivatives 26–35


The third family of FSM derivatives synthesized is based on the functionalization of the acid **42**. This compound can be an interesting platform, where the main functions of FSM are present, and a propyl carboxylic acid is attached as a linker. In this respect, the two first compounds of this family (**56** and **57**, Scheme 4) have already been synthesized as valuable intermediates in the synthesis of FSM-ART conjugates with spermidine and homospermidine linkages. By using analogous peptide coupling conditions, eight new compounds were synthesized possessing various amino and/or amido frameworks connected to the hydroxamic function (Scheme 5).



Scheme 5. Synthesis of FSM-amido derivatives **26–33**; Reagents and conditions: (a) R¹H, HBTU, DIPEA, CH₂Cl₂, rt, 3–6 h, 62%–84%; (b) H₂, 10% Pd/C, MeOH, rt, 3–5 h, 80%–90%; (c) R¹H, HBTU, DIPEA, CH₂Cl₂, rt, 2 h, 70% for **66** and 6 h, 84% for **68**; (d) TFA, TFE, CH₂Cl₂, 0 °C to rt, 1 h, 70%; (e) H₂, 10% Pd/C, MeOH, rt, 2 h, 90% for **32** and 4 h, 60% for **33**.

Among the different amine reagents, Boc-monoprotected dianiline (used for derivative **29**) and Trt-piperazine (used for derivative **66**) were synthesized according to known procedures [39,40], while all other amines were commercially available.

Finally, two more compounds were synthesized, where the hydroxamic part was replaced by a fragment that potentially can interact with metal ions as is the case and the role of the hydroxamic function of FSM. In this respect, *o*-phenylenediamine (a known pharmacophore) was chosen due to its chelating capacity [41]. Synthesis of the two final compounds **34** and **35** was straightforward. Alkylation of *o*-phenylenediamine under sonicating conditions using the already available bromophosphonate **37** afforded in fair yield compound **34**, which upon ethyl ester deprotection, followed by basic work-up, led to compound **35** (Scheme 6).



Scheme 6. Synthesis of phosphonate derivatives **34** and **35**; Reagents and conditions: (a) DBU, DMF, 1 h, ultrasound, rt, 33%; (b) (i) TMSBr, DCM, 0 °C to rt, 8 h (ii) 6N aq. NaOH/MeOH 75% over 2 steps.

The synthesized compounds were evaluated for their antiplasmodial activity against the CQ-resistant *P. falciparum* FcB1/Colombia strain [42,43], using as control drugs FSM, FR900098, ART, and CQ (see Figure 3). Moreover, their cytotoxicity was measured, as previously reported, upon the primary human fibroblast cell line AB943, which allowed the calculation of their selectivity index (SI) [35].




Figure 3. Structures of the control drugs (FSM, FR900098, ART, CQ).

Specifically, IC_{50} (μM) values for the antiplasmodial activities were determined from four independent experiments as the mean values \pm standard deviations. IC_{50} (μM) values for the cytotoxicity activities were determined from two independent experiments as the mean values \pm standard deviations. IC_{50} , SIs (ratio between IC_{50} (μM) of cytotoxicity/ IC_{50} (μM) of the antiplasmodial activity), and XLogGP3 values for the FSM derivatives, hybrid, and conjugates are reported in Table 1. The IC_{50} values of ART, FSM, FR900098, and CQ were also measured and are provided as controls.

Table 1. Evaluation of antiplasmodial activities of synthesized compounds with CQ-resistant *P. falciparum* FcB1/Colombia strain and selectivity indexes (SI).

Compound	MW	ClogP ¹	IC_{50} (μM)	SI ²
FSM	205.08	-2.22	15.0 ± 1.7	>6.6
17	253.23	-0.43	>100	-
FR900098	219.11	-2.24	7.0 ± 0.0	>14.2
18	504.45	-1.22	>100	-
19	540.98	1.42	2.7 ± 0.5	23.9
20	628.97	2.24	4.2 ± 0.9	23.7
21	533.60	3.22	28.0 ± 11.6	-
22	1083.31	4.97	0.36 ± 0.09	94.1
23	1097.33	5.33	0.65 ± 0.26	34.0
24	667.56	-4.62	>100	-
25	680.58	-4.26	46.2 ± 8.0	-
26	425.42	-0.35	86.0 ± 1.4	-
27	401.40	-0.37	81.0 ± 2.8	-
28	490.54	1.92	38.7 ± 10.0	-
29	591.64	2.80	22.7 ± 1.9	1.7
30	400.41	0.25	>100	-
31	476.51	1.94	44.2 ± 9.5	-
32	393.42	-1.25	>100	-
33	493.42	-3.09	>100	-
34	286.31	1.56	8.2 ± 2.7	3.7
35	230.20	-0.24	>100	-
ART	282.34	2.90	55.0 ± 13.6 (nM)	>4545
CQ	318.89	5.70	72.0 ± 7.4 (nM)	347

¹ XLogGP3 values calculated with the web tool SwissADME [44]. ² SI = IC_{50} (AB943)/ IC_{50} (*P.f.* FcB1)

Concerning the first family of compounds (FSM, 17, FR900098, 18), it was noticed that phosphonate esters are inactive. For example, FR900098's diethyl phosphonate analogue 17 and the dimer 18, which possesses two diethylphosphonate ester FSM frames linked together with a succinic acid spacer, have IC_{50} values >100 μM . FSM appears 2-fold less active than FR900098, with IC_{50} values

of 15.0 and 7.0 μM respectively, while their selectivity indexes also follow the same trends (>6.6 vs. >14.2 μM respectively).

The second family, constructed by introducing next to the carbonyl group of the FSM hydroxamate group active antimalarial pharmacophores like aminochloroquinoline or artemisinin, presents very interesting results. The hybrid compounds with aminochloroquinoline **19** and **20** showed strong and comparable activities of 2.7 and 4.2 μM , respectively. Compound **19** possesses the structure of piperazine linked through an amide chain to the FSM diester fragment. The **19** and **20** compounds are 3.5–5.5 times more active than FSM itself and more than 25–40-fold more active in comparison to the diester compound **17**. Their activities are lower but closer to the CQ, indicating a major influence of the ACQ fragment, largely compensating the absence of acid functionality on the FSM. In addition, they showed higher selectivity indexes in comparison to FSM but much lower in comparison to CQ.

Concerning the hybrid compounds containing artemisinin, we observed a weaker activity for compound **21**, where one artemisinin moiety is linked directly to the FSM diester fragment ($\text{IC}_{50} = 28.0$ μM). On the contrary, the conjugation of the two ART frames with one FSM diester fragment through a spermidine and to a lesser extent to an homospermidine linker (**22**, **23**) afforded the most active molecules of our series with IC_{50} values of 0.36 and 0.65 μM ; and the best selectivity among all new compounds, with SI values of 94 and 34, respectively. Here, again, it is observed that the IC_{50} values are 6.5–12 times higher than ART itself but much lower than FSM's (23–41 fold). These values indicate a stronger influence of the ART fragment to the conjugates. It is noteworthy that all molecules of this family, which exhibit strong antimalarial activities, possess the diethyl phosphonate group.

According to our recently reported work on other antimalarial hybrid compounds [35], the presence of two artemisinin moieties linked through spermidine or homospermidine to an amide chain bearing a third endoperoxide (GMeP) gave IC_{50} values of the order of 10 nM. In the case of compounds **22** and **23**, the presence of FSM diester (in the place of GMeP) was observed again, even if the activities were lower in this case, probably confirming that hybrid compounds with two different potential targets of *Plasmodium* can be an interesting option in the search for new antimalarial compounds.

Compounds possessing only the spermidine or homospermidine fragments attached through an amido linker to FSM diester (**24**, **25**) are much less active; however, a better IC_{50} value was observed for compound **25** bearing the homospermidine frame. Among the other compounds of this third family, those bearing two aromatic rings attached to the amido function (**28**, **29**, **31**) present activities in the range between 22 and 44 μM , while compounds **26**, **27**, and **30** are inactive. Nevertheless, the second-best compound of this family series (**29**) is cytotoxic since it has an SI value of only 1.7. Finally, the two compounds possessing a piperazine or *N*-methyl piperazine fragment (**32**, **33**) are inactive, indicating that piperazine alone (as spermidine and homospermidine alone) lacks activity like the diester **17**. For the last two compounds of the third family (**34**, **35**), where the hydroxamic fragment was replaced by an *ortho*-benzenediamine fragment, we observed good activity for the diester **34** ($\text{IC}_{50} = 8.2$ μM), while the mono sodium salt of the corresponding diacid (**35**) is inactive. However, despite the good antimalarial activity of **34**, it seems to be cytotoxic, with an SI value of only 3.7.

In Table 1, the MWs, IC_{50} values, and the evaluation of the XLogGP3 SwissADME values according to the online calculation [44] are also reported. The software can combine physicochemical properties along with pharmacokinetics predictions for the drug likeness of the examined compounds. Since the families of the synthesized and tested compounds are quite different, we first examined and compared the values for each family. The active and known compounds FSM and FR900098 show the most negative values (-2.22 and -2.24 , respectively) in comparison to values of -0.43 and -1.22 for diester **17** and the dimer **18**. For the second and most promising family of compounds, values vary between $+1.42$ and $+5.33$, with the two most active compounds having the highest ones. Concerning the third family of compounds, the most active show values between $+1.92$ and $+2.80$, while the inactive ones have negative values. In summary, apart from the first family, where all compounds possess negative XLOGP3 ADME values, the others show positive values for the active ones, the highest being for the most actives. Even if the calculation of the XLOGP3 values takes into consideration a number of

different parameters, including the molecular weight, we feel that XLOGP3 could be one of many valuable tools to include when searching to optimize structures of the same family.

Results concerning comparative activities and the XLogGP3 SwissADME for all compounds tested indicated that different factors intervene for the activities of the compounds. Most important of them are related to the fragment-attached FSM derivative and to the linker next to that. The influence of the acid group of the FSM has to be more extensively studied, as its role is not apparent in regard to some of the results obtained. Moreover, it is noteworthy to observe that compounds with a potential protonation site on the fragment adjacent to the FSM core (compounds **19**, **20**, **34**) can be very active, along with those possessing two highly active pharmacophores (compounds **22**, **23**) connected through a polyamino linker to the FSM core.

In conclusion, a series of FSM analogs, derivatives, and conjugates with ART and ACQ were synthesized and evaluated against *P. falciparum*. The most active compounds, which in addition to possessing a good SI, are those that combine two ART frames with the one of FSM diester, through a spermidine or homospermidine linker and exhibit IC₅₀ values of 0.36 and 0.65 μM, respectively (compounds **22** and **23**). Interestingly, the hybrid compounds with one ACQ frame (compounds **19** and **20**) are 3.5–5.5 times more active than FSM itself with fairly good SIs. While for FSM and FR900098 the monosodium salt **17** is the most active form, for the hybrid compounds mentioned above, the diethyl phosphonates **19** and **20** show the best activity.

Further work is in progress to examine whether for the most active compounds, (i) the diester forms are better than the acidic ones and (ii) if they are active against strains of *P. falciparum* showing a different resistance status. Finally, according to our recent findings on hybrid compounds possessing the endoperoxide GMeP [35], we are now engaged in incorporating this frame in a series of FSM analogues and evaluating them.

3. Materials and Methods

3.1. General Methods

Melting points were determined with a Buchi SMP-20 apparatus and are uncorrected. ¹H NMR spectra were obtained at 600.13 MHz and ¹³C NMR spectra at 150.90 MHz on a Bruker AVANCEIII HD spectrometer. Chemical shifts (δ) are indicated in parts per million (ppm) downfield from TMS and coupling constants (*J*) are reported in hertz (Copies of NMR spectra are available in the Supplementary Materials). ESI-HRMS spectra were recorded on a Waters Q-TOF UPLC Xevo G2 and ESI mass spectra were recorded at 30 V, on a Micromass-Platform LC spectrometer using MeOH as solvent. All solvents were dried and/or purified according to standard procedures prior to use. Anhydrous Na₂SO₄ was used for drying solutions, and the solvents were then routinely removed at ca. 40 °C under reduced pressure using a rotary vacuum evaporator. All reagents employed in the present work were commercially available and used without further purification. When required, reactions were carried out under dry argon atmosphere in preflamed glassware. Flash column chromatography (FCC) was performed on Merck silica gel 60 (230–400 mesh) and analytical thin layer chromatography (TLC) was performed on Merck silica gel 60F₂₅₄ (0.2 mm) precoated on aluminum foil. Spots on the TLC plates were visualized with UV light at 254 nm and ninhydrine solution or charring agents.

3.2. Experimental Procedures

3.2.1. Synthesis of FSM Dimer **18**

4-((Benzyloxy)(3-(diethoxyphosphoryl)propyl)amino)-4-oxobutanoic acid (**42**): To an ice-cold solution of protected amine **39** (1 mmol) and 4-dimethylaminopyridine (DMAP) (0.1 mmol) in freshly distilled tetrahydrofuran (THF) (2 mL), *N,N*-diisopropylethylamine (DIPEA) (1.5 mmol) was added. Then, the addition of succinic anhydride (1.1 mmol) was followed in small portions over 30 min and the reaction mixture was stirred at ambient temperature for 3h. Upon completion of the reaction,

THF was removed under reduced pressure and the residue thus obtained was diluted with CH_2Cl_2 and washed with 5% aqueous citric acid, water, and brine. The organic layer was dried over Na_2SO_4 and evaporated to dryness under vacuum. The residue was subjected to FCC to give acid **42** as yellow oil (283 mg, 88%); R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.15; $^1\text{H NMR}$ (CDCl_3): δ 7.37 (5H, s), 4.84 (2H, s), 4.16–3.98 (4H, m), 3.71 (2H, t, $J = 6.2$ Hz), 2.71 (2H, t, $J = 6.4$ Hz), 2.62 (2H, t, $J = 6.4$ Hz), 1.98–1.86 (2H, m), 1.79–1.68 (2H, m), 1.29 (6H, t, $J = 7.1$ Hz); $^{13}\text{C NMR}$ (CDCl_3): δ 175.9, 134.3, 129.3, 129.1, 128.8, 76.5, 61.9, 29.0, 28.7, 27.3, 23.2, 22.3, 20.2, 16.4; $^{31}\text{P NMR}$ (CDCl_3): δ 34.18; ESI-MS (30eV): m/z 825.04 [$2\text{M} + \text{Na}$] $^+$, 440.16 [$\text{M} + \text{K}$] $^+$, 424.16 [$\text{M} + \text{Na}$] $^+$, 402.12 [$\text{M} + \text{H}$] $^+$.

Tetraethyl ((4,7-dioxo-1,10-diphenyl-2,9-dioxo-3,8-diazadecane-3,8-diyl) bis(propane-3,1-diyl)) bis(phosphonate) (**43**): To a solution of acid **42** (60 mg, 0.15 mmol) and HBTU (63 mg, 0.165 mmol) in CHCl_3 (1.4 mL), amine **39** (45 mg, 0.15 mmol), and Et_3N (32 μL , 0.225 mmol) were added. After 3.5 h, the reaction mixture was diluted with CHCl_3 , washed with 5% aqueous citric acid, water, 5% aqueous NaHCO_3 , water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The residue thus obtained was subjected to FCC, affording the corresponding pure conjugate; Yellow oil (72 mg, 70%); R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.37; $^1\text{H NMR}$ (CDCl_3) δ 7.41–7.34 (m, 10H), 4.90 (s, 4H), 4.12–4.02 (m, 8H), 3.71 (t, $J = 6.4$ Hz, 4H), 2.77 (s, 4H), 1.99–1.89 (m, 4H), 1.75–1.69 (m, 4H), 1.29 (t, $J = 7.1$ Hz, 12H); $^{13}\text{C NMR}$ (CDCl_3) δ 175.5, 134.5, 129.2, 128.9, 128.7, 76.5, 61.6, 26.9, 23.5, 22.5, 20.3, 16.5; ESI-MS (30eV): m/z 723.42 [$\text{M} + \text{K}$] $^+$, 707.54 [$\text{M} + \text{Na}$] $^+$, 685.54 [$\text{M} + \text{H}$] $^+$, 384.64 [$\text{M} - \text{C}_{14}\text{H}_{23}\text{NO}_4\text{P}$] $^+$.

Tetraethyl-((succinylbis(hydroxyazanediyl))bis(propane-3,1-diyl))bis(phosphonate) (**18**): A solution of **43** (50 mg, 0.073 mmol) in methanol (3 mL) was subjected to hydrogenolysis over 10% Pd/C (15 mg) at ambient temperature for 3 h. Thus, the reaction mixture was filtered through Celite and the filter cake was washed several times with methanol. After evaporation of the solvent to dryness under reduced pressure, the residue was subjected to FCC, affording the corresponding the dimer **18**; Yellow oil (18 mg, 50%); R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.12; $^1\text{H NMR}$ (CDCl_3) δ 9.92 (s, 1H), 4.11–4.01 (m, 8H), 3.75–3.59 (m, 4H), 2.82 (s, 4H), 1.97–1.85 (m, 4H), 1.82–1.71 (m, 4H), 1.30 (t, $J = 7.0$ Hz, 12H); $^{13}\text{C NMR}$ (CDCl_3) δ 170.7, 62.0, 49.0, 27.8, 22.9, 21.9, 19.5, 16.4; HRMS (ESI/Q-TOF): m/z 527.1907 [$\text{M} + \text{Na}$] $^+$ for the compound $\text{C}_{18}\text{H}_{38}\text{N}_2\text{O}_{10}\text{P}_2$ requires 527.1894.

3.2.2. Synthesis of FSM-ACQ Derivatives **19** and **20**

4-((3-(Diethoxyphosphoryl)propyl)(hydroxyamino)-4-oxobutanoic acid (**47**): A solution of **42** (80 mg, 0.2 mmol) in methanol (3 mL) was subjected to hydrogenolysis over 10% Pd/C (12 mg) at ambient temperature for 5 h. Thus, the reaction mixture was filtered through Celite and the filter cake was washed several times with methanol. After evaporation of the solvent to dryness under reduced pressure, the residue was subjected to FCC, affording pure **47**; Orange oil (60.4 mg, 97%); R_f ($\text{CHCl}_3/\text{MeOH}$ 9:1): 0.23; $^1\text{H NMR}$ (CDCl_3) δ 4.14–4.02 (m, 4H), 3.73 (t, $J = 6.2$ Hz, 2H), 2.86 (t, $J = 6.2$ Hz, 2H), 2.66 (t, $J = 7.3$ Hz, 2H), 2.00–1.90 (m, 2H), 1.83 & 1.80 (dt, $J = 18.3, 7.1$ Hz, 2H), 1.32 (t, $J = 7.1$ Hz, 6H); $^{13}\text{C NMR}$ (CDCl_3) δ 177.2, 173.7, 62.4, 47.9, 29.4, 27.4, 22.9, 22.7, 21.9, 19.1, 16.4; ESI-MS (30eV): m/z 661.14 [$2\text{M} + \text{K}$] $^+$, 645.14 [$2\text{M} + \text{Na}$] $^+$, 350.37 [$\text{M} + \text{K}$] $^+$, 334.43 [$\text{M} + \text{Na}$] $^+$.

Diethyl (3-(4-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)-*N*-hydroxy-4-oxobutanamido) propyl) phosphonate (**19**): To a solution of acid **47** (32 mg, 0.1 mmol) and 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (42 mg, 0.1 mmol) in CHCl_3 (0.2 mL), amine **44** (25 mg, 0.1 mmol) and DIPEA (30 μL , 0.15 mmol) were added at ambient temperature. After 2 h, the mixture was evaporated under reduced pressure and the residue thus obtained subjected to FCC providing the conjugate **19**; Orange oil (32 mg, 60%); R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.12; $^1\text{H NMR}$ (CDCl_3) δ 9.82 (s, 1H), 8.75 (d, $J = 5.0$ Hz, 1H), 8.07 (d, $J = 2.2$ Hz, 1H), 7.95 (d, $J = 9.0$ Hz, 1H), 7.47 (dd, $J = 9.0, 2.1$ Hz, 1H), 6.85 (d, $J = 5.0$ Hz, 1H), 4.14–4.05 (m, 4H), 3.90 (s, 2H), 3.83–3.78 (m, 2H), 3.75 (t, $J = 6.1$ Hz, 2H), 3.25–3.16 (m, 4H), 2.88 (t, $J = 6.4$ Hz, 1H), 2.77 (t, $J = 6.4$ Hz, 1H), 2.03–1.90 (m, 2H), 1.80 (dt, $J = 18.4, 7.0$ Hz, 4H), 1.32 (t, $J = 7.1$ Hz, 6H); $^{13}\text{C NMR}$ (CDCl_3) δ 173.2, 171.3, 156.4, 151.9, 150.1, 135.2, 129.0,

126.7, 124.7, 121.8, 109.4, 62.0, 52.1, 47.6, 45.5, 41.8, 29.0, 27.2, 22.8, 21.9, 19.3, 16.4; HRMS (ESI/Q-TOF): m/z 541.1997 $[M + H]^+$; for the compound $C_{24}H_{34}ClN_4O_6P$ requires 541.1977.

4-(((Tert-butoxycarbonyloxy)(3-(diethoxy-phosphoryl)propyl)amino)-4-oxobutanoic acid (**48**): To a solution of **47** (55 mg, 0.176 mmol) in CH_2Cl_2 (5.5 mL), catalytic amount of DMAP, Et_3N (25 μ L, 0.176 mmol), and di-tert-butyl-dicarbonate (38 mg, 0.176 mmol) were added and the reaction mixture was stirred overnight at ambient temperature. It was then diluted with DCM and washed with pre-cooled 5% aqueous citric acid, water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The residue thus obtained was subjected to FCC, affording **48** as yellow oil (21.7 mg, 30%); R_f ($CHCl_3/MeOH$ 95:5): 0.15; 1H NMR ($CDCl_3$) δ 4.15–4.02 (m, 4H), 3.79 (t, $J = 6.3$ Hz, 2H), 2.67 (d, $J = 6.2$ Hz, 2H), 2.62 (d, $J = 4.1$ Hz, 2H), 1.90–1.84 (m, 2H), 1.83–1.75 (m, 2H), 1.54 (s, 9H), 1.31 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR ($CDCl_3$) δ 175.1, 61.8, 61.7, 28.4, 27.6, 16.4; ^{31}P NMR ($CDCl_3$) δ 34.18.

Diethyl (3-(*N*-((tert-butoxycarbonyloxy)-4-((2-((7-chloroquinolin-4-yl)amino)ethyl) amino)-4-oxobutanamido)propyl)phosphonate (**49**): To a solution of acid **48** (13 mg, 0.03 mmol) and HBTU (13 mg, 0.033 mmol) in $CHCl_3/DMF$ 5:1 (0.3 mL), amine **45** (7 mg, 0.03 mmol), and Et_3N (7 μ L, 0.045 mmol) were added. After 4h, the reaction mixture was diluted with DCM, washed with pre-cooled 5% aqueous citric acid, water, 5% aqueous $NaHCO_3$, water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The residue thus obtained was subjected to FCC, affording the corresponding pure conjugate **49** as yellow oil (9.2 mg, 50%); R_f ($CHCl_3/MeOH$ 95:5): 0.18; 1H NMR ($CDCl_3$) δ 8.41 (d, $J = 5.6$ Hz, 1H), 7.93 (d, $J = 2.0$ Hz, 1H), 7.91 (s, 1H), 7.39 (dd, $J = 8.9, 2.0$ Hz, 1H), 7.16 (s, 1H), 7.05 (s, 1H), 6.28 (d, $J = 5.7$ Hz, 1H), 4.13–4.01 (m, 4H), 3.67 (s, 4H), 3.44–3.38 (m, 2H), 2.69 (s, 2H), 2.56 (s, 2H), 1.83–1.75 (m, 2H), 1.74 (d, $J = 13.1$ Hz, 2H), 1.51 (s, 9H), 1.30 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR ($CDCl_3$) δ 174.7, 151.3, 149.9, 135.8, 126.5, 125.8, 122.8, 117.0, 98.0, 61.7, 45.1, 38.6, 27.5, 20.2, 16.4; ESI-MS (30eV): m/z 1251.76 $[2M + Na]^+$, 653.26 $[M + K]^+$, 637.49 $[M + Na]^+$, 615.52 $[M + H]^+$.

7-Chloro-*N*-(2-(4-((3-(diethoxyphosphoryl)propyl)(hydroxy)amino)-4oxobutanamido) ethyl) quinolin-4-aminium 2,2,2-trifluoroacetate (**20**): To an ice-cold solution of **49** (6 mg, 0.01 mmol) in CH_2Cl_2 (0.4 mL), trifluoroacetic acid (TFA) (12 μ L) was added and the reaction mixture was stirred overnight at ambient temperature. Then, volatile components were evaporated under vacuum and the oily residue thus obtained was subjected to FCC, affording pure conjugate **20**. Colorless oil (3.8 mg, 60%); R_f ($CHCl_3/MeOH$ 85:15): 0.3; 1H NMR ($CDCl_3$) δ 9.15 (s, 1H), 8.28 (d, $J = 6.6$ Hz, 1H), 8.15 (d, $J = 9.0$ Hz, 1H), 7.93 (s, 2H), 7.45 (d, $J = 8.9$ Hz, 1H), 6.40 (d, $J = 6.8$ Hz, 1H), 4.13–4.02 (m, 4H), 3.69–3.61 (m, 4H), 3.53 (s, 2H), 2.89 (t, $J = 6.4$ Hz, 2H), 2.59 (t, $J = 6.1$ Hz, 2H), 1.97–1.88 (m, 2H), 1.81–1.75 (m, 23H), 1.32 (t, $J = 7.0$ Hz, 6H); ^{13}C NMR ($CDCl_3$) δ 176.0, 173.5, 155.6, 142.7, 139.8, 138.7, 127.9, 124.4, 120.0, 115.3, 97.5, 62.3, 47.9, 45.4, 38.1, 31.2, 29.7, 28.3, 22.6, 21.8, 19.2, 16.4; HRMS (ESI/Q-TOF): m/z 537.1649 $[M + Na]^+$; for the compound $C_{22}H_{32}ClN_4O_6P$ requires 537.1640.

3.2.3. Synthesis of FSM-ART Conjugates 21–23

Diethyl (3-(*N*-(benzyloxy)-3-((3*S*,5*aS*,6*R*,8*aS*, 9*R*,10*R*,12*R*)-3,6,9-trimethyldecahydro-12*H*-3,12 epoxy [1,2] dioxepino [4,3-*i*]isochromen-10-yl)propanamido) propyl) phosphonate (**51**): To a solution of artemisinin derivative **50** (25 mg, 0.07 mmol) in DCM (0.47 mL), HBTU (29 mg, 0.077 mmol) and Et_3N (15 μ L, 0.105 mmol) were added. The reaction mixture was stirred overnight at ambient temperature. Subsequently, it was diluted with CH_2Cl_2 , washed with pre-cooled 5% aqueous citric acid, water, 5% aqueous $NaHCO_3$, water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The residue thus obtained was subjected to FCC, affording conjugate **51** as yellow oil (22 mg, 50%); R_f ($AcOEt$): 0.17; 1H NMR ($CDCl_3$) δ 7.44–7.39 (m, 2H), 7.38–7.33 (m, 3H), 5.29 (s, 1H), 4.85 (s, 2H), 4.12–4.03 (m, 4H), 3.78–3.65 (m, 2H), 2.80 (s, 1H), 2.76–2.71 (m, 1H), 2.55–2.47 (m, 1H), 2.33 (td, $J = 14.0, 3.9$ Hz, 1H), 2.04–1.99 (m, 1H), 1.98–1.91 (m, 2H), 1.91–1.86 (m, 1H), 1.83–1.78 (m, 1H), 1.77–1.69 (m, 3H), 1.68–1.62 (m, 4H), 1.59–1.53 (m, 1H), 1.50–1.40 (m, 2H), 1.39 (s, 3H), 1.30 (t, $J = 7.1$ Hz, 6H), 1.27–1.20 (m, 2H), 0.94 (d, $J = 6.1$ Hz, 3H), 0.88 (d, $J = 7.5$ Hz,

3H); ^{13}C NMR (CDCl_3) δ 129.4, 128.9, 128.7, 103.4, 88.6, 81.2, 75.9, 61.6, 52.5, 44.6, 37.4, 36.6, 34.5, 30.2, 26.2, 24.9, 24.7, 24.0, 20.2, 16.5, 13.3; ESI-MS (30eV): m/z 1285.61 $[2\text{M} + \text{K}]^+$, 1269.36 $[2\text{M} + \text{Na}]^+$, 662.46 $[\text{M} + \text{K}]^+$, 646.46 $[\text{M} + \text{Na}]^+$.

Diethyl (3-(N-hydroxy-3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-trimethyldecahydro-12H-3, 12-epoxy [1,2]dioxepino[4,3-i]isochromen-10-yl)propanamido)propyl)phosphonate (**21**): A solution of conjugate **51** (20 mg, 0.032 mmol) in methanol (3 mL) was subjected to hydrogenolysis over 10% Pd/C (5 mg) at ambient temperature for 4 h. Thus, the reaction mixture was filtered through Celite and the filter cake was washed several times with methanol. After evaporation of the solvent to dryness under reduced pressure, the residue was subjected to FCC, affording pure **21**; Orange oil (15 mg, 90%); R_f (DCM/MeOH 95:5): 0.35; ^1H NMR (CDCl_3) δ 8.52 (br s, 1H), 8.08 (s, 1H), 5.28 (s, 1H), 4.10–4.01 (m, 4H), 3.87 (dt, $J = 13.5, 6.6$ Hz, 1H), 3.74–3.69 (m, 1H), 3.57–3.50 (m, 1H), 2.69–2.63 (m, 1H), 2.57–2.47 (m, 2H), 2.11 (s, 2H) 1.99–1.89 (m, 4H), 1.85–1.74 (m, 7H), 1.51 (s, 3H), 1.431–1.28 (m, 7H), 1.05 (d, $J = 6.3$ Hz, 3H), 0.96 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (CDCl_3) δ 175.0, 161.0, 107.6, 97.2, 82.6, 69.3, 61.7, 57.4, 54.3, 48.0, 45.2, 41.4, 40.0, 35.5, 34.5, 27.8, 25.1, 23.4, 22.0, 20.5, 19.7, 18.8, 16.4, 12.5, 11.9; HRMS (ESI/Q-TOF): m/z 556.2650 $[\text{M} + \text{Na}]^+$; for the compound $\text{C}_{25}\text{H}_{44}\text{NO}_9\text{P}$ requires 556.2646.

General procedure for the synthesis of FSD-polyamine conjugates. To a solution of **42** (60 mg, 0.15 mmol) and HBTU (62 mg, 0.165 mmol) in CHCl_3 (300 μL), the suitable protected spermidine **52** (94 mg, 0.15 mmol) or homospermidine **53** (96 mg, 0.15 mmol) and Et_3N (32 μL , 0.225 mmol) were added. After 7–12 h, the mixture was diluted with CHCl_3 and washed with pre-cooled 5% aqueous citric acid, water, 5% aqueous NaHCO_3 , water, and brine. The organic layer was dried over Na_2SO_4 , filtered and evaporated to dryness under reduced pressure. The residues thus obtained were subjected to FCC, affording the corresponding conjugates **54** and **55**.

Diethyl (3-(N-(benzyloxy)-4-oxo-4-((4-(tritylamino)butyl)(3-(tritylamino)propyl)amino)butanamido) propyl) phosphonate (**54**): Reaction time: 7h; White foam (109 mg, 72%); R_f (AcOEt): 0.2; ^1H NMR (CDCl_3) δ 7.50–7.42 (m, 12H), 7.42–7.32 (m, 5H), 7.31–7.21 (m, 12H), 7.20–7.12 (m, 6H), 4.91 (s, 1H), 4.88 (s, 1H), 4.10–4.02 (m, 4H), 3.73–3.64 (m, 2H), 3.38 (t, $J = 7.1$ Hz, 1H), 3.33 (t, $J = 7.7$ Hz 1H), 3.25 (t, $J = 7.1$ Hz, 1H), 3.14 (t, $J = 7.6$ Hz, 1H), 2.76 (s, 1H), 2.60 (t, $J = 6.0$ Hz, 1H), 2.51 (t, $J = 5.9$ Hz, 1H), 2.18–2.10 (m, 3H), 2.08–2.05 (m, 1H), 1.97–1.87 (m, 2H), 1.74 (s, 3H), 1.72–1.65 (m, 2H), 1.60–1.55 (m, 1H), 1.53–1.42 (m, 3H), 1.30–1.25 (m, 6H); ^{13}C NMR (CDCl_3) δ 171.2, 146.2, 146.1, 145.9, 134.5, 129.1, 128.8, 128.6, 128.5, 127.8, 127.7, 126.3, 126.2, 126.1, 76.4, 70.8, 61.5, 60.4, 47.5, 46.2, 43.7, 43.5, 43.3, 41.3, 40.9, 38.6, 30.3, 28.7, 28.4, 28.1, 27.6, 27.3, 26.7, 25.8, 23.5, 22.5, 21.0, 20.2, 16.4, 14.2; ESI-MS (30eV): m/z 1035.75 $[\text{M} + \text{Na}]^+$, 1013.39 $[\text{M} + \text{H}]^+$, 301.48 $[\text{M}-\text{C}_{49}\text{H}_{50}\text{H}_3\text{O}_2]^+$, 243.28 $[\text{Trt}]^+$.

Diethyl (3-(N-(benzyloxy)-4-(bis(4-(tritylamino)butyl)amino)-4-oxobutanamido) propyl) phosphonate (**55**): Yellow pale foam (148 mg, 96%); R_f (AcOEt/ Et_3N 1%): 0.18; ^1H NMR (CDCl_3) δ 7.49–7.41 (m, 9H), 7.40–7.32 (m, 6H), 7.30–7.21 (m, 12H), 7.19–7.12 (m, 5H), 4.90 (s, 1H), 4.87 (s, 1H), 4.15–4.05 (m, 6H), 3.70 (dt, $J = 14.0, 7.0$ Hz, 2H), 3.22 (dt, $J = 15.0, 7.1$ Hz, 2H), 3.22–3.17 (m, 1H), 2.82–2.72 (m, 2H), 2.55 (t, $J = 6.4$ Hz, 1H), 2.12 (dt, $J = 14.3, 7.0$ Hz, 2H), 1.97–1.78 (m, 4H), 1.74–1.64 (m, 4H), 1.60–1.41 (m, 7H), 1.34–1.24 (m, 10H); ^{13}C NMR (CDCl_3) δ 171.2, 146.2, 146.1, 129.2, 128.6, 127.8, 127.7, 126.2, 70.2, 61.5, 60.6, 59.2, 47.7, 46.0, 43.4, 28.7, 28.4, 28.2, 27.7, 27.4, 26.7, 25.7, 24.0, 23.5, 23.1, 22.5, 20.3, 16.4, 14.2.

Trityl-deprotection of conjugates **54** and **55**. To an ice-cold solution of **54** or **55** (0.12 mmol) in DCM (1.0 mL), TFE (50 μL , 0.65 mmol) and TFA (50 μL , 0.65 mmol) were added. The reaction mixture was stirred at ambient temperature for 6h. Volatile components were evaporated under vacuo, and the oily residue was triturated with Et_2O /Hex and refrigerated overnight. The corresponding trifluoroacetate salts **56** and **57** were received after decanting of the solvents.

4-(N-(3-ammoniopropyl)-4-((benzyloxy)(3-(diethoxyphosphoryl)propyl)amino)-4-oxobutanamido)butan-1-aminium 2,2,2-trifluoroacetate (**56**): Yellow oil (82 mg, 90%); ^1H NMR (MeOD): δ 7.49–7.45 (m, 2H), 7.44–7.39 (m, 3H), 4.97 (br s, 2H), 4.13–4.05 (m, 4H), 3.78 (t, $J = 6.5$ Hz, 2H), 3.52–3.47 (m, 3H), 3.45 (t, $J = 7.4$ Hz, 1H), 3.03–2.97 (m, 2H), 2.90 (t, $J = 7.0$ Hz, 2H), 2.82 (br s, 2H), 2.71–2.65 (m, 2H), 1.94–1.86

(m, 4H), 1.85–1.68 (m, 6H), 1.65–1.61 (m, 1H), 1.31 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (MeOD) δ 174.0, 172.8, 134.7, 129.2, 128.7, 128.3, 75.9, 65.5, 61.9, 44.4, 41.9, 39.0, 36.8, 36.5, 30.9, 27.1, 26.8, 26.3, 25.4, 25.2, 24.4, 24.2, 24.0, 22.2, 21.3, 19.7, 15.3, 15.3, 14.0, 12.9; HRMS (ESI/Q-TOF): m/z 461.2503 $[\text{M} + \text{Na}]^+$; for the compound $\text{C}_{25}\text{H}_{45}\text{N}_4\text{O}_6\text{P}$ requires 461.2499.

4,4'-((4-((Benzyloxy)(3-(diethoxyphosphoryl)propyl)amino)-4-oxobutanoyl)azanediyl) bis(butan-1-aminium) 2,2,2-trifluoroacetate (57): Yellow oil (83 mg, 90%); ^1H NMR (MeOD): δ 7.48–7.44 (m, 2H), 7.42–7.36 (m, 3H), 4.96 (s, 2H), 4.11–4.04 (m, 4H), 3.76 (t, $J = 6.6$ Hz, 2H), 3.41 (t, $J = 6.9$ Hz, 2H), 3.37 (br s, 2H), 3.31–3.28 (m, 2H), 2.98 (t, $J = 6.9$ Hz, 2H), 2.94 (br s, 2H), 2.80 (s, 1H), 2.79 (br s, 1H), 2.67–2.63 (m, 2H), 1.93–1.86 (m, 2H), 1.83–1.76 (m, 2H), 1.75–1.66 (m, 4H), 1.62 (br s, 4H), 1.30 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (MeOD) δ 172.7, 161.2, 160.9, 160.7, 160.5, 134.7, 129.2, 128.6, 128.3, 127.9, 127.2, 126.6, 119.0, 117.4, 115.5, 112.5, 75.9, 61.9, 46.8, 44.6, 39.0, 27.0, 25.2, 24.4, 24.3, 24.0, 22.2, 21.3, 19.7, 15.3; HRMS (ESI/Q-TOF): m/z 453.2848 $[\text{M} + \text{H}]^+$; for the compound $\text{C}_{26}\text{H}_{47}\text{N}_4\text{O}_6\text{P}$ requires 453.2836.

General procedure for the synthesis of ART-FSD conjugates **58** & **59**. To a solution of **50** (20 mg, 0.06 mmol) and HBTU (25 mg, 0.066 mmol) in CHCl_3 (300 μL), compound **56** (22 mg, 0.03 mmol) or **57** (21 mg, 0.03 mmol), and Et_3N (20 μL , 0.135 mmol) were added. After 12 h, the mixture was diluted with CHCl_3 and washed with pre-cooled 5% aqueous citric acid, water, 5% aqueous NaHCO_3 , water, and brine. The organic layer was dried over Na_2SO_4 , filtered, and evaporated to dryness under reduced pressure. The residues thus obtained were subjected to FCC, affording the corresponding conjugates **58** and **59**.

*Diethyl(3-(N-(benzyloxy)-4-oxo-4-((4-(3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*isochromen-10-yl)propanamido)butyl)(3-(3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*isochromen-10-yl)propanamido)propyl)amino)butanamido)propyl)phosphonate (58)*: Yellow oil (18 mg, 50%); R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.3; ^1H NMR (CDCl_3) δ 7.43–7.35 (m, 5H), 5.29 (s, 2H), 4.92 (s, 2H), 4.12–3.98 (m, 6H), 3.70 (s, 2H), 3.44–3.35 (m, 2H), 3.33–3.23 (m, 5H), 3.20–3.13 (m, 2H), 2.81 (s, 2H), 2.74–2.68 (m, 2H), 2.66–2.57 (m, 2H), 2.51–2.38 (m, 2H), 2.36–2.24 (m, 4H), 2.05–1.98 (m, 3H), 1.96–1.85 (m, 6H), 1.77 (s, 8H), 1.70–1.60 (m, 7H), 1.58–1.51 (m, 4H), 1.48–1.43 (m, 3H), 1.41–1.35 (m, 7H), 1.29 (t, $J = 7.0$ Hz, 6H), 1.26–1.20 (m, 3H), 0.94 (t, $J = 5.8$ Hz, 6H), 0.87 (t, $J = 7.3$ Hz, 6H); ^{13}C NMR (CDCl_3) δ 173.1, 173.0, 172.2, 129.2, 128.9, 128.7, 103.4, 88.7, 81.2, 61.6, 52.5, 47.3, 44.6, 44.5, 43.0, 38.9, 37.3, 36.5, 36.2, 34.6, 34.4, 30.2, 27.4, 27.0, 26.2, 24.9, 24.6, 20.2, 16.5, 13.2; ESI-MS (30eV): m/z 1211.62 $[\text{M} + \text{K}]^+$, 1195.80 $[\text{M} + \text{Na}]^+$.

*Diethyl(3-(N-(benzyloxy)-4-(bis(4-(3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*isochromen-10-yl)propanamido)butyl)amino)-4-oxobutanamido)propyl)phosphonate (59)*: White foam (18 mg, 50%), R_f ($\text{CHCl}_3/\text{MeOH}$ 95:5): 0.3; ^1H NMR (CDCl_3) δ 7.44–7.32 (m, 5H), 6.32 (s, 1H), 6.21 (s, 1H), 5.28 (s, 2H), 4.91 (s, 2H), 4.13–3.98 (m, 6H), 3.69 (s, 2H), 3.36–3.19 (m, 8H), 2.80 (s, 4H), 2.74–2.67 (m, 2H), 2.60 (s, 2H), 2.47–2.40 (m, 2H), 2.35–2.24 (m, 4H), 2.04–1.97 (m, 2H), 1.95–1.85 (m, 8H), 1.83–1.77 (m, 4H), 1.75–1.70 (m, 2H), 1.67–1.60 (m, 4H), 1.58–1.51 (m, 7H), 1.49–1.42 (m, 4H), 1.37 (d, $J = 3.4$ Hz, 6H), 1.29 (t, $J = 7.0$ Hz, 6H), 1.25–1.21 (m, 3H), 0.96–0.91 (m, 6H), 0.89–0.83 (m, 6H); ^{13}C NMR (CDCl_3) δ 173.1, 171.4, 134.5, 129.2, 128.9, 128.7, 103.4, 88.7, 81.2, 61.6, 52.5, 47.5, 45.6, 44.5, 38.8, 38.6, 37.4, 36.5, 34.5, 34.4, 30.2, 27.6, 27.4, 27.0, 26.7, 26.1, 25.0, 24.8, 24.8, 24.6, 23.4, 22.5, 20.2, 16.5, 13.2; ESI-MS (30eV): m/z 1225.82 $[\text{M} + \text{K}]^+$, 1210.29 $[\text{M} + \text{Na}]^+$.

General procedure for the hydrogenolysis of **56**–**59**. A solution of **56** or **57** or **58** or **59** (0.01 mmol) in methanol (3 mL) was subjected to hydrogenolysis over 10% Pd/C (5 mg) at ambient temperature and pressure for 4 h–6.5 h. Thus, the reaction mixture was filtered through Celite and the filter cake was washed several times with methanol. After evaporation of the solvent to dryness under reduced pressure, the residues were subjected to FCC, affording the corresponding pure deprotected molecules **24**, **25**, **22**, and **23**, respectively.

*Diethyl(3-(N-hydroxy-4-oxo-4-((4-(3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*isochromen-10-yl)propanamido)butyl)(3-(3-((3S,5aS,6R,8aS,9R,10R,12R)-3,6,9-*

*trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*]isochromen-10-yl)propanamido)propyl)amino)butanamido)propyl)phosphonate (22):* Yellow oil (6.5 mg, 60%), R_f (CHCl₃/MeOH 97:3): 0.35; ¹H NMR (CDCl₃) δ 9.94 (br s, 1H), 8.18 (br s, 1H) 5.33 (s, 2H), 4.23–4.07 (m, 6H), 3.79 (s, 2H), 3.49–3.33 (m, 7H), 3.24–3.19 (s, 3H), 2.89 (br s, 2H), 2.79 (br s, 2H), 2.45–2.37 (m, 3H), 2.36–2.27 (m, 4H), 2.21 (s, 2H), 2.03–1.96 (m, 5H), 1.95–1.90 (m, 4H), 1.88–1.83 (m, 5H), 1.78–1.72 (m, 8H), 1.55 (s, 5H), 1.49 (t, $J = 7.4$ Hz, 3H), 1.40 (t, $J = 6.9$ Hz, 8H), 1.34 (s, 4H), 1.58–1.13 (m, 2H), 1.06–1.02 (m, 3H), 0.99–0.94 (m, 9H); ¹³C NMR (CDCl₃) δ 213.4, 209.3, 173.7, 160.5, 107.3, 97.4, 82.7, 68.3, 62.2, 54.6, 47.9, 46.3, 45.6, 41.8, 40.8, 39.0, 35.9, 34.9, 34.1, 30.2, 29.9, 27.6, 25.5, 24.1, 24.0, 22.5, 20.8, 20.6, 19.1, 16.8, 12.9, 12.4, 8.9; HRMS (ESI/Q-TOF): m/z 1083.6273 [M + H]⁺; for the compound C₅₄H₉₁N₄O₁₆P requires 1083.6240.

*Diethyl(3-(4-(bis(4-(3-((3*S*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-*i*]isochromen-10-yl)propanamido)butyl)amino)-*N*-hydroxy-4-oxobutanamido)propyl)phosphonate (23):* Yellow oil (6.6 mg, 60%), R_f (CHCl₃/MeOH 97:3): 0.35; ¹H NMR (CDCl₃) δ 9.97 (br s, 1H), 8.09 (s, 1H) 5.24 (s, 2H), 4.12–4.04 (m, 6H), 3.70 (br s, 2H), 3.31–3.22 (m, 7H), 3.15–3.08 (m, 2H), 2.78–2.69 (m, 4H), 2.35–2.29 (m, 3H), 2.24–2.18 (m, 4H), 2.12 (s, 2H), 2.08–1.99 (m, 4H), 1.94–1.88 (m, 7H), 1.78–1.74 (m, 4H), 1.67–1.64 (m, 4H), 1.62–1.57 (m, 5H), 1.54–1.48 (m, 5H), 1.46 (s, 7H), 1.31 (t, $J = 6.9$ Hz, 6H), 1.26–1.14 (m, 6H), 1.05 (d, $J = 5.8$ Hz, 2H), 0.96 (d, $J = 6.7$ Hz, 3H), 0.90–0.85 (m, 9H); ¹³C NMR (CDCl₃) δ 213.3, 209.1, 173.6, 161.2, 107.0, 97.1, 82.4, 67.9, 61.8, 57.4, 54.3, 47.5, 45.3, 41.4, 40.4, 35.6, 34.5, 33.7, 29.9, 29.6, 27.3, 25.8, 25.1, 23.7, 22.2, 20.5, 20.3, 18.8, 16.4, 12.6, 12.1; HRMS (ESI/Q-TOF): m/z 1119.6185 [M + Na]⁺; for the compound C₅₅H₉₃N₄O₁₆P requires 1119.6216.

*4-(*N*-(3-ammoniopropyl)-4-((3-(diethoxyphosphoryl)propyl)(hydroxy)amino)-4-oxobutanamido)butan-1-aminium 2,2,2-bis(trifluoroacetate) (24):* Yellow oil (61 mg, 91%); HRMS (ESI/Q-TOF): m/z 439.2687 [M + H]⁺; for the compound C₁₈H₃₉N₄O₆P requires 439.2680.

4,4'-((4-((3-(diethoxyphosphoryl)propyl)(hydroxy)amino)-4-oxobutanoyl)azanediyl)bis(butan-1-aminium) 2,2,2-bis(trifluoroacetate) (25): Yellow oil (65 mg, 95%); HRMS (ESI/Q-TOF): m/z 453.2848 [M + H]⁺; for the compound C₁₉H₄₁N₄O₆P requires 453.2836.

3.2.4. Synthesis of FSM-Amino and/or Amido Derivatives 26–33

General procedure for the synthesis of Fosmidomycin conjugates with amines. To a solution of **42** (1 mmol) in CH₂Cl₂ (1.4 mL), the corresponding amines (1 mmol), HBTU (1.1 mmol), and DIPEA (1.5 mmol) were added. The reaction mixture was stirred at ambient temperature to complete the reaction (monitored by TLC) and then diluted with CH₂Cl₂, washed with 5% aqueous NaHCO₃, pre-cooled 5% aqueous citric acid, water, and brine. The organic layer was dried over Na₂SO₄, filtered, and evaporated to dryness under reduced pressure. The residues thus obtained were subjected to FCC, affording the corresponding pure conjugates **60–67**.

Tert-butyl 2-(4-((benzyloxy)(3-(diethoxyphosphoryl)propyl)amino)-4-oxobutanoyl) hydrazine-1-carboxylate (60): Reaction time: 5 h; Yellow oil (320 mg, 62%); R_f (CHCl₃/MeOH 97:3): 0.28; ¹H NMR (CDCl₃) δ 7.76 (br s, 1H), 7.37 (s, 5H), 4.85 (s, 2H), 4.12–4.03 (m, 4H), 3.74–3.68 (m, 2H), 2.83–2.78 (m, 2H), 2.55–2.50 (m, 2H), 1.96–1.88 (m, 2H), 1.69 (br s, 2H), 1.48 (s, 1H), 1.46 (s, 8H), 1.30 (t, $J = 7.1$ Hz, 6H); ¹³C NMR (CDCl₃) δ 155.3, 129.3, 129.0, 128.8, 81.5, 76.6, 61.7, 61.6, 28.6, 28.2, 28.1, 27.7, 23.4, 22.5, 20.2, 16.4; ESI-MS (30eV): m/z 554.32 [M + K]⁺, 538.45 [M + Na]⁺, 516.4 [M + H]⁺, 384.6 [M – C₅H₁₁N₂O₂]⁺.

*Diethyl(3-(4-((2-aminophenyl)amino)-*N*-(benzyloxy)-4-oxobutanamido)propyl)phosphonate (61):* Reaction time: 4 h; Yellow oil (388 mg, 79%); R_f (CHCl₃/MeOH 98:2): 0.15; ¹H NMR (CDCl₃) δ 7.77 (br s, 1H), 7.38 (s, 5H), 7.21 (dd, $J = 8.2, 1.3$ Hz, 1H), 7.02 (td, $J = 7.7, 1.4$ Hz, 1H), 6.76–6.72 (m, 2H), 4.86 (s, 2H), 4.11–4.01 (m, 4H), 3.72 (t, $J = 6.2$ Hz, 2H), 2.89 (t, $J = 6.0$ Hz, 2H), 2.65 (t, $J = 6.6$ Hz, 2H), 1.97–1.89 (m, 2H), 1.74–1.67 (m, 2H), 1.28 (t, $J = 7.1$ Hz, 6H); ¹³C NMR (CDCl₃) δ 171.2, 141.2, 129.2, 129.1, 128.8, 127.1, 125.8, 123.7, 118.8, 117.2, 76.5, 61.7, 61.6, 31.3, 28.5, 23.4, 22.3, 19.6, 16.5, 16.4; ESI-MS (30eV): m/z 983.25 [2M + H]⁺, 530.35 [M + K]⁺, 514.29 [M + Na]⁺, 492.37 [M + H]⁺, 384.3 [M – C₆H₇N₂]⁺.

Diethyl(3-(N-(benzyloxy)-4-(dibenzylamino)-4-oxobutanamido)propyl)phosphonate (62): Reaction time: 5 h; Pale yellow (441 mg, 76%); *R_f* (AcOEt): 0.16; ¹H NMR (CDCl₃) δ 7.43–7.40 (m, 2H), 7.39–7.34 (m, 5H), 7.33–7.27 (m, 4H), 7.22–7.19 (m, 4H), 4.94 (s, 2H), 4.61 (s, 2H), 4.51 (s, 2H), 4.12–4.02 (m, 4H), 3.74 (t, *J* = 6.7 Hz, 2H), 2.91–2.86 (m, 2H), 2.76 (t, *J* = 6.4 Hz, 2H), 1.99–1.90 (m, 2H), 1.79–1.70 (m, 2H), 1.28 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (CDCl₃) δ 172.4, 137.3, 136.5, 129.2, 128.9, 128.9, 128.7, 128.6, 128.1, 127.6, 127.3, 126.6, 76.5, 61.5, 49.9, 48.2, 27.8, 27.6, 23.5, 22.5, 20.3, 16.5, 16.4; ESI-MS (30eV): *m/z* 1183.64 [2M + Na]⁺, 619.25 [M + K]⁺, 603.22 [M + Na]⁺, 581.38 [M + H]⁺, 280.52 [M–C₁₄H₂₃NO₄P]⁺.

Tert-butyl(4-(4-(4-((benzyloxy)(3-(diethoxyphosphoryl)propyl)amino)-4-oxobutanamido)benzyl)phenyl)carbamate (63): Reaction time: 3 h; Yellow oil (573 mg, 84%); *R_f* (CHCl₃/MeOH 98:2): 0.25; ¹H NMR (CDCl₃) δ 8.04 (s, 1H), 7.39 (t, *J* = 6.9 Hz, 2H), 7.36 (s, 4H), 7.25 (s, 2H), 7.24 (s, 1H), 7.07 (t, *J* = 8.7 Hz, 4H), 6.42 (s, 1H), 4.85 (s, 2H), 4.12–3.97 (m, 4H), 3.86 (s, 2H), 3.72 (s, 2H), 2.83 (s, 2H), 2.64–2.59 (m, 2H), 1.96–1.88 (m, 2H), 1.75–1.67 (m, 2H), 1.49 (s, 9H), 1.27 (t, *J* = 7.1 Hz, 6H); ESI-MS (30eV): *m/z* 1401.75 [2M + K]⁺, 1385.75 [2M + Na]⁺, 1363.84 [2M + 2H]⁺, 720.36 [M + K]⁺, 704.49 [M + Na]⁺, 682.39 [M + H]⁺.

Diethyl (3-(4-(benzylamino)-N-(benzyloxy)-4-oxobutanamido)propyl) phosphonate (64): Reaction time: 6 h; Yellow oil (363 mg 74%); *R_f* (CHCl₃/MeOH 95:5): 0.29; ¹H NMR (CDCl₃) δ 7.41–7.35 (m, 5H), 7.34–7.29 (m, 2H), 7.28–7.23 (m, 3H), 6.27 (s, 1H), 4.85 (s, 2H), 4.43 (d, *J* = 5.7 Hz, 2H), 4.11–4.01 (m, 4H), 3.70 (t, *J* = 6.6 Hz, 2H), 2.81 (t, *J* = 6.0 Hz, 2H), 2.52 (t, *J* = 6.5 Hz, 2H), 1.96–1.87 (m, 2H), 1.75–1.66 (m, 2H), 1.29 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (CDCl₃) δ 173.8, 172.0, 138.4, 134.3, 129.2, 129.0, 128.7, 128.6, 127.7, 127.4, 76.5, 61.6, 45.8, 43.6, 30.8, 28.1, 23.5, 22.5, 20.3, 16.5; ESI-MS (30eV): *m/z* 529.34 [M + K]⁺, 513.41 [M + Na]⁺, 491.49 [M + H]⁺, 384.36 [M–C₇H₈N]⁺.

Diethyl (3-(N-(benzyloxy)-4-oxo-4-(4-tritylpiperazin-1-yl)butanamido)propyl) phosphonate (66): Reaction time: 3 h; Yellow oil (60 mg, 70%); *R_f* (CHCl₃/MeOH 99:1): 0.18; ¹H NMR (CDCl₃) δ 7.47 (br s, 5H), 7.39–7.32 (m, 5H), 7.30–7.24 (m, 7H), 7.19–7.14 (m, 3H), 4.88 (s, 2H), 4.10–4.02 (m, 4H), 3.68 (t, *J* = 6.5 Hz, 2H), 3.62 (s, 2H), 2.73 (s, 2H), 2.54 (t, *J* = 6.2 Hz, 2H), 2.17 (s, 4H), 1.96–1.87 (m, 2H), 1.75–1.65 (m, 4H), 1.28 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (CDCl₃) δ 170.2, 134.4, 129.2, 128.8, 128.6, 127.7, 126.3, 70.4, 61.6, 48.2, 47.7, 45.8, 42.2, 38.6, 30.9, 27.4, 23.5, 22.5, 20.3, 16.4; ESI-MS (30eV): *m/z* 1445.58 [2M + Na]⁺, 734.41 [M + Na]⁺, 243.41 [Trt]⁺.

Diethyl (3-(N-(benzyloxy)-4-(4-methylpiperazin-1-yl)-4-oxobutanamido)propyl) phosphonate (67): Reaction time: 2 h; Yellow oil (338 mg 70%); *R_f* (CHCl₃/MeOH 9:1): 0.16; ¹H NMR (CDCl₃) δ 7.41–7.32 (m, 5H), 4.91 (s, 2H), 4.11–4.01 (m, 4H), 3.70 (t, *J* = 6.8 Hz, 2H), 3.67–3.62 (m, 2H), 3.56–3.52 (m, 2H), 2.79 (s, 2H), 2.62 (t, *J* = 6.5 Hz, 2H), 2.44 (br s, 2H), 2.40 (br s, 2H), 2.32 (s, 3H), 1.96–1.88 (m, 2H), 1.76–1.67 (m, 2H), 1.28 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (CDCl₃) δ 137.1, 128.8, 128.4, 128.0, 76.3, 61.5, 59.2, 59.1, 29.7, 24.0, 23.1, 20.3, 16.5; ESI-MS (30eV): *m/z* 522.33 [M + K]⁺, 506.39 [M + Na]⁺, 484.41 [M + H]⁺, 384.35 [M–C₅H₁₁N₂]⁺.

Trityl-deprotection of 4-(4-((benzyloxy)(3-(diethoxyphosphoryl) propyl)amino)-4-oxobutanoyl)piperazin-1-ium2,2,2-trifluoroacetate (68): To an ice-cold solution of **66** (0.18 mmol) in CH₂Cl₂ (0.56 mL), trifluoroethanol (TFE) (0.36 mmol) and TFA (0.36 mmol) were added. The reaction mixture was stirred at ambient temperature for 1h. Volatile components were evaporated under vacuo, and the oily residue was triturated with Et₂O and refrigerated overnight. The white precipitate was filtered under vacuum and dried to afford the trifluoroacetate salt **68**. White solid (74 mg, 70%); *R_f* (CHCl₃/MeOH 9:1): 0.16; ¹H NMR (MeOD): δ 7.50–7.45 (m, 2H), 7.44–7.38 (m, 3H), 4.98 (s, 2H), 4.13–4.02 (m, 4H), 3.86–3.75 (m, 6H), 3.21 (br s, 2H), 2.82 (br s, 2H), 2.72–2.67 (m, 2H), 1.95–1.87 (m, 2H), 1.84–1.78 (m, 2H), 1.31 (t, *J* = 7.1 Hz, 6H).

Deprotection of intermediates **60–65**, **67**, and **68**. A solution of **60–65**, **67**, and **68** (0.1 mmol) in methanol (3 mL) was subjected to hydrogenolysis over 10% Pd/C at ambient temperature and pressure until completion of the reaction. Thus, the reaction mixture was filtered through Celite and the filter cake was washed several times with methanol. After evaporation of the solvent to dryness under

reduced pressure, the residues were subjected to FCC, affording the corresponding pure deprotected molecules **26–33**.

Tert-butyl 2-(4-((3-(diethoxyphosphoryl)propyl)(hydroxy)amino)-4-oxobutanoyl)hydrazine-1-carboxylate (26): Reaction time: 5 h; Orange oil (38 mg 90%); R_f (CHCl₃/MeOH 95:): 0.19; ¹H NMR (CDCl₃) δ 9.58 (s, 1H), 8.52 (s, 1H), 7.05 (s, 1H), 4.13–4.03 (m, 4H), 3.70 (t, $J = 6.0$ Hz, 2H), 2.86 (t, $J = 6.3$ Hz, 2H), 2.58–2.52 (m, 2H), 1.96–1.87 (m, 2H), 1.78 (m, 2H), 1.47 (s, 1H), 1.45 (s, 8H), 1.31 (t, $J = 7.0$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.3, 155.6, 81.5, 62.1, 47.9, 29.3, 28.2, 27.7, 22.8, 21.8, 19.4, 16.4; HRMS (ESI/Q-TOF): m/z 426.2000 [M + H]⁺; for the compound C₁₆H₃₂N₃O₈P requires 426.2005.

Diethyl(3-(4-((2-aminophenyl)amino)-N-hydroxy-4-oxobutanamido)propyl)phosphonate (27): Reaction time: 3 h; Yellow oil (54 mg, 89%); R_f (CHCl₃/MeOH 95:5): 0.11; ¹H NMR (CDCl₃) δ 9.76 (br s, 1H), 8.20 (s, 1H), 7.20 (d, $J = 7.9$ Hz, 1H), 7.02–6.99 (m, 1H), 6.74–6.71 (m, 1H), 4.04–3.99 (m, 4H), 3.72 (t, $J = 6.1$ Hz, 2H), 2.96–2.92 (m, 2H), 2.70–2.66 (m, 2H), 1.97–1.89 (m, 2H), 1.78 (dt, $J = 18.5, 6.9$ Hz, 2H), 1.26 (t, $J = 7.1$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.9, 172.0, 141.0, 127.0, 125.7, 123.8, 118.8, 117.1, 62.3, 62.2, 47.9, 31.9, 28.6, 22.8, 21.8, 19.2, 16.3; HRMS (ESI/Q-TOF): m/z 424.1615 [M + Na]⁺; for the compound C₁₇H₂₈N₃O₆P requires 424.1608.

Diethyl(3-(4-(dibenzylamino)-N-hydroxy-4-oxobutanamido)propyl)phosphonate (28): Reaction time: 4 h; Yellow oil (39 mg, 80%); R_f (CHCl₃/MeOH 98:2): 0.21; ¹H NMR (CDCl₃) δ 9.86 (s, 1H), 7.39–7.34 (m, 2H), 7.33–7.27 (m, 4H), 7.21–7.13 (m, 4H), 4.59 (s, 2H), 4.49 (s, 2H), 4.14–4.02 (m, 4H), 3.75 (t, $J = 6.0$ Hz, 2H), 2.91–2.81 (m, 4H), 2.01–1.92 (m, 2H), 1.81 (dt, $J = 18.2, 7.1$ Hz, 2H), 1.28 (t, $J = 7.0$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.3, 173.2, 136.9, 136.0, 129.0, 128.6, 128.1, 127.7, 127.4, 126.5, 61.9, 50.0, 48.5, 47.6, 47.5, 29.2, 27.3, 22.8, 21.9, 19.3, 16.4; HRMS (ESI/Q-TOF): m/z 491.2311 [M + H]⁺; for the compound C₂₅H₃₅N₂O₆P requires 491.2305.

Tert-butyl(4-(4-((3-(diethoxyphosphoryl)propyl)(hydroxy)amino)-4-oxobutanamido)benzyl)phenyl carbamate (29): Reaction time: 3 h; light yellow oil (53 mg, 90%); R_f (CHCl₃/MeOH 97:3): 0.09; ¹H NMR (CDCl₃) δ 9.78 (br s, 1H), 8.70 (s, 1H), 7.40 (d, $J = 8.3$ Hz, 2H), 7.24 (d, $J = 7.8$ Hz, 2H), 7.07–7.03 (m, 4H), 6.48 (s, 1H), 4.00 (quint, $J = 14.4, 7.0$ Hz, 4H), 3.85 (s, 2H), 3.74 (t, $J = 6.0$ Hz, 2H), 2.94–2.88 (m, 2H), 2.70–2.62 (m, 2H), 1.99–1.90 (m, 3H), 1.82–1.74 (m, 2H), 1.50 (s, 9H), 1.23 (t, $J = 7.1$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.9, 171.3, 152.9, 136.9, 136.4, 135.9, 129.3, 129.2, 129.0, 128.2, 125.3, 119.9, 118.8, 62.3, 47.9, 40.6, 32.6, 28.4, 22.7, 21.8, 19.1, 16.3; HRMS (ESI/Q-TOF): m/z 592.2787 [M + H]⁺; for the compound C₂₉H₄₂N₃O₈P requires 592.2782.

Diethyl(3-(4-(benzylamino)-N-hydroxy-4-oxobutanamido)propyl)phosphonate (30): Reaction time: 3 h; Reddish oil (36 mg, 90%); R_f (CHCl₃/MeOH 95:5): 0.09; ¹H NMR (CDCl₃) δ 9.83 (br s, 1H), 7.32–7.27 (m, 2H), 7.25–7.21 (m, 3H), 6.78 (s, 1H), 4.38 (s, 2H), 4.09–4.00 (m, 4H), 3.71–3.65 (m, 2H), 2.84 (s, 2H), 2.56 (s, 2H), 1.97–1.87 (m, 2H), 1.81–1.71 (m, 2H), 1.29 (t, $J = 7.0$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.5, 172.9, 138.3, 128.6, 127.6, 127.3, 62.1, 47.8, 47.7, 43.6, 31.4, 27.9, 22.8, 21.9, 19.4, 16.4; HRMS (ESI/Q-TOF): m/z 423.1657 [M + Na]⁺; for the compound C₁₈H₂₉N₂O₆P requires 423.1655.

Diethyl(3-(4-(benzhydrylamino)-N-hydroxy-4-oxobutanamido)propyl)phosphonate (31): Reaction time: 3 h; Reddish oil (40 mg, 85%); R_f (PhMe/AcOEt 4:6): 0.1; ¹H NMR (CDCl₃) δ 7.40–7.09 (m, 10), 6.25–6.11 (m, 1H), 4.17–3.95 (m, 4H), 3.76–3.61 (m, 2H), 2.84 (s, 2H), 2.59 (s, 2H), 2.07–1.85 (m, 2H), 1.84–1.65 (m, 2H), 1.34–1.21 (m, 6H); ¹³C NMR (CDCl₃) δ 173.7, 172.2, 141.7, 128.6, 127.4, 127.3, 62.1, 56.0, 50.8, 47.3, 31.5, 28.8, 28.0, 21.5, 19.3, 16.4; HRMS (ESI/Q-TOF): m/z 499.1979 [M + Na]⁺; for the compound C₂₄H₃₃N₂O₆P requires 499.1968.

Diethyl(3-(N-hydroxy-4-(4-methylpiperazin-1-yl)-4-oxobutanamido)propyl)phosphonate (32): Reaction time: 2 h; Orange oil (35 mg, 90%); R_f (CHCl₃/MeOH 8:2): 0.29; ¹H NMR (CDCl₃) δ 4.16–4.01 (m, 7H), 3.70 (t, $J = 6.9$ Hz, 1H), 3.62 (br s, 2H), 3.52 (t, $J = 5.2$ Hz, 2H), 2.79 (t, $J = 6.8$ Hz, 1H), 2.70 (t, $J = 7.0$ Hz, 1H), 2.65 (quint, $J = 10.8, 4.5$ Hz, 1H), 2.45 (br s, 1H), 2.40 (br s, 1H), 2.32 (s, 3H), 1.97–1.90 (m, 2H), 1.80–1.73 (m, 2H), 1.31 (t, $J = 7.0$ Hz, 6H); ¹³C NMR (CDCl₃) δ 173.7, 173.2, 62.2, 51.7, 47.8, 29.0, 28.7, 27.5,

22.5, 21.6, 19.0, 16.4; HRMS (ESI/Q-TOF): m/z 416.1848 $[M + Na]^+$; for the compound $C_{16}H_{32}N_3O_6P$ requires 416.1921.

4-(4-((3-(Diethoxyphosphoryl)propyl)(hydroxy)amino)-4-oxobutanoyl)piperazin-1-ium 2,2,2-trifluoroacetate (**33**): Reaction time: 4 h; Yellow oil (30 mg, 60%); R_f ($CHCl_3/MeOH$ 8:2): 0.22; 1H NMR ($CDCl_3$) δ 9.84 (br s, 1H), 4.13–4.02 (m, 4H), 3.82 (br s, 2H), 3.74–3.66 (m, 2H), 3.24–3.10 (m, 2H), 2.84 (s, 2H), 2.68–2.62 (m, 2H), 2.55 (s, 1H), 1.98–1.88 (m, 2H), 1.78 (dt, $J = 18.0, 6.9$ Hz, 2H), 1.34–1.29 (m, 6H); ^{13}C NMR ($CDCl_3$) δ 173.2, 171.3, 62.1, 53.7, 48.5, 43.4, 29.7, 27.4, 22.7, 21.7, 19.4, 16.4; HRMS (ESI/Q-TOF): m/z 380.1948 $[M + H]^+$; for the compound $C_{15}H_{30}N_3O_6P$ requires 380.1945.

Diethyl (3-((2-aminophenyl)amino)propyl)phosphonate (**34**): To a solution of bromide **37** (90 mg, 0.35 mmol) and *ortho*-benzenediamine (35 mg, 0.35 mmol) in dimethylformamide (DMF) (0.46 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (106 mg, 0.7 mmol) was added and the reaction mixture was subjected to ultrasonic radiation at 40 °C for 1 h. Upon completion of the reaction, the mixture was diluted CH_2Cl_2 , and washed three times with water and once with brine. The organic layer was dried over Na_2SO_4 and evaporated to dryness under pressure. The residue was purified by FCC, affording compound **34**; orange oil (33 mg, 33%); R_f ($CHCl_3/MeOH$ 97:3): 0.3; 1H NMR ($CDCl_3$): δ 6.79 (dt, $J = 7.5, 1.6$ Hz, 1H), 6.70 (dd, $J = 7.7, 1.9$ Hz, 1H), 6.68–6.60 (m, 2H), 4.15–4.04 (m, 4H), 3.20 (t, $J = 6.6$ Hz, 2H), 2.01–1.92 (m, 2H), 1.921–1.84 (m, 2H), 1.31 (t, $J = 7.0$ Hz, 6H); ^{13}C NMR ($CDCl_3$) δ 137.4, 134.3, 120.5, 118.6, 116.4, 111.6, 61.6, 44.4, 44.3, 23.9, 23.0, 22.5, 22.5, 16.5; HRMS (ESI/Q-TOF): m/z 287.1525 $[M + H]^+$; for the compound $C_{13}H_{23}N_2O_3P$ requires 287.1519.

(3-((2-Aminophenyl)amino)propyl)phosphonic acid (**35**): To an ice-cold solution of **34** (30 mg, 0.1 mmol) in CH_2Cl_2 (0.33 mL), bromotrimethylsilane (TMSBr) (0.16 mL, 1.2 mmol) was added dropwise and the reaction mixture was stirred at room temperature for 8 h. Then, it was concentrated under vacuum and treated with a solution of NaOH (0.41 mg, 0.1 mmol) in MeOH/ H_2O 9:1 (1 mL) at room temperature for 40 min. The monosodium salt **35** was received after evaporation of the solvents to dryness under reduced pressure as an orange oil (19 mg, 75%); 1H NMR (H_2D): δ 7.18–7.09 (m, 3H), 7.08–7.04 (m, 1H), 3.32 (t, $J = 7.4$ Hz, 2H), 1.92–1.84 (m, 2H), 1.82–1.75 (m, 2H); ^{13}C NMR (H_2D) δ 131.8, 126.7, 125.4, 122.9, 119.8, 47.7, 24.3, 23.4, 20.5; ESI-MS (30eV): m/z 499.34 $[2M + K]^+$, 483.42 $[2M + Na]^+$, 461.45 $[2M + H]^+$, 269.48 $[M + K]^+$, 253.5 $[M + Na]^+$, 231.53 $[M + H]^+$.

3.3. Biological Evaluation

3.3.1. Biological Assays

Cytotoxicity evaluation was performed upon human primary fibroblasts (cell line AB943) [35]. Assays were realized in 96-well plates in DMEM + Glutamax without phenol red medium (Gibco) containing 25 mM HEPES, pH 7.3, 10% fetal calf serum under a 5% CO_2 atmosphere, at 37 °C. After trypsin treatment, AB943 cells were seeded at 2000 cells per well in 100 μL . After 24 h of incubation, drugs diluted in culture medium were added (100 μL per well). Drug stock solutions were prepared in dimethyl sulfoxide (DMSO). The final DMSO concentration in the cultures remained below 1%. Control cultures were constituted of cultures treated with DMSO instead of drug. The cytotoxicity assay was based on the conversion of a redox-sensitive dye (resazurin) to a fluorescent product by viable cells. After 72 h of incubation, resazurin solution was added in each well at a final concentration of 45 μM . Fluorescence was measured at 530 nm excitation and 590 nm emission wavelengths after 4 h of incubation. The percentage of inhibition of cell growth was calculated by comparing the fluorescence of cells maintained in the presence of drug to that in the absence of drug. The concentration causing 50% growth inhibition (IC_{50}) was obtained from the drug concentration–response curve and the results were expressed as the mean values \pm standard deviations determined from several independent experiments.

3.3.2. In Vitro Growth Inhibition of *P. falciparum*

The chloroquine-resistant FcB1/Colombia strain of *Plasmodium falciparum* was maintained in vitro on human erythrocytes in RPMI 1640 medium supplemented by 8% (*v/v*) heat-inactivated human serum, at 37 °C, under an atmosphere of 3% CO₂, 6% O₂, and 91% N₂ [45]. In vitro drug susceptibility assays were measured by [³H]-hypoxanthine incorporation. Drug stock solutions were prepared in DMSO. Compounds were serially diluted two-fold with 100 µL of culture medium in 96-well plates. Asynchronous parasite cultures (100 µL, 1% parasitaemia and 1% final hematocrite) were then added to each well and incubated for 24 h at 37 °C prior to the addition of 0.5 µCi of [³H]-hypoxanthine (GE Healthcare, France, 1 to 5 Ci·mmol/mL) per well [42]. After a further incubation of 24 h, plates were frozen and thawed. Cell lysates were then collected onto fiberglass filters and counted in a liquid scintillation spectrometer. The growth inhibition for each drug concentration was determined by comparison of the radioactivity incorporated in the treated culture with that in the control culture maintained on the same plate. The IC₅₀ value was obtained from the drug concentration–response curve and the results were expressed as the mean values ± standard deviations determined from several independent experiments. Chloroquine and artemisinin were used as antimalarial drug controls.

Supplementary Materials: The following are available online, Figure S1: ¹H-NMR spectrum of compound 42, Figure S2: ¹³C-NMR spectrum of compound 42, Figure S3: ³¹P-NMR spectrum of compound 42, Figure S4: ¹H-NMR spectrum of compound 43, Figure S5: ¹³C-NMR spectrum of compound 43, Figure S6: ¹H-NMR spectrum of compound 18, Figure S7: ¹³C-NMR spectrum of compound 18, Figure S8: ¹H-NMR spectrum of compound 47, Figure S9: ¹³C-NMR spectrum of compound 47, Figure S10: ¹H-NMR spectrum of compound 19, Figure S11: ¹³C-NMR spectrum of compound 19, Figure S12: ¹H-NMR spectrum of compound 20, Figure S13: ¹³C-NMR spectrum of compound 20, Figure S14: ¹H-NMR spectrum of compound 21, Figure S15: ¹³C-NMR spectrum of compound 21, Figure S16: ¹H-NMR spectrum of compound 54, Figure S17: ¹³C-NMR spectrum of compound 54, Figure S18: ¹H-NMR spectrum of compound 55, Figure S19: ¹³C-NMR spectrum of compound 55, Figure S20: ¹H-NMR spectrum of compound 56, Figure S21: ¹³C-NMR spectrum of compound 56, Figure S22: ¹H-NMR spectrum of compound 57, Figure S23: ¹³C-NMR spectrum of compound 57, Figure S24: ¹H-NMR spectrum of compound 22, Figure S25: ¹³C-NMR spectrum of compound 22, Figure S26: ¹H-NMR spectrum of compound 23, Figure S27: ¹³C-NMR spectrum of compound 23, Figure S28: ¹H-NMR spectrum of compound 60, Figure S29: ¹³C-NMR spectrum of compound 60, Figure S30: ¹H-NMR spectrum of compound 61, Figure S31: ¹³C-NMR spectrum of compound 61, Figure S32: ¹H-NMR spectrum of compound 62, Figure S33: ¹³C-NMR spectrum of compound 62, Figure S34: ¹H-NMR spectrum of compound 63, Figure S35: ¹H-NMR spectrum of compound 64, Figure S36: ¹³C-NMR spectrum of compound 64, Figure S37: ¹H-NMR spectrum of compound 66, Figure S38: ¹³C-NMR spectrum of compound 66, Figure S39: ¹H-NMR spectrum of compound 67, Figure S40: ¹³C-NMR spectrum of compound 67, Figure S41: ¹H-NMR spectrum of compound 68, Figure S42: ¹H-NMR spectrum of compound 26, Figure S43: ¹³C-NMR spectrum of compound 26, Figure S44: ¹H-NMR spectrum of compound 27, Figure S45: ¹³C-NMR spectrum of compound 27, Figure S46: ¹H-NMR spectrum of compound 28, Figure S47: ¹³C-NMR spectrum of compound 28, Figure S48: ¹H-NMR spectrum of compound 29, Figure S49: ¹³C-NMR spectrum of compound 29, Figure S50: ¹H-NMR spectrum of compound 30, Figure S51: ¹³C-NMR spectrum of compound 30, Figure S52: ¹H-NMR spectrum of compound 31, Figure S53: ¹³C-NMR spectrum of compound 31, Figure S54: ¹³C-NMR spectrum of compound 32, Figure S55: ¹³C-NMR spectrum of compound 32, Figure S56: ¹H-NMR spectrum of compound 33, Figure S57: ¹H-NMR spectrum of compound 33, Figure S58: ¹H-NMR spectrum of compound 34, Figure S59: ¹³C-NMR spectrum of compound 34, Figure S60: ¹H-NMR spectrum of compound 35, Figure S61: ¹³C-NMR spectrum of compound 35.

Author Contributions: Conceptualization, C.M.A.; methodology, C.M.A., M.B., P.G. and E.M.; NMR and MS analysis, C.M.A., D.P. and A.I.A.; investigation, D.P., A.I.A., P.G., and E.M.; and C.M. for several purifications; writing—original draft preparation, C.M.A. and M.B.; writing—review and editing, C.M.A., M.B., P.G., E.M., A.I.A., D.P.; supervision, C.M.A.; project administration, C.M.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We would like to thank the CNRS, the University of Patras and the University Paul Sabatier for financial support. The authors would also like to acknowledge the Instrumental Analysis Laboratory (EEA, School of Natural Sciences, University of Patras) for carrying out the NMR analyses and the ICT Mass Spectrometry facility (<http://ict.ups-tlse.fr/?HPLC-102>) for the recording of HRMS spectra.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO World Malaria Report. 2019. Available online: <https://www.who.int/malaria/publications/world-malaria-report-2019/en/> (accessed on 4 December 2019).
2. Dondorp, A.M.; Yeung, S.; White, L.; Nguon, C.; Day, N.P.J.; Socheat, D.; von Seidlein, L. Artemisinin resistance: Current status and scenarios for containment. *Nat. Rev. Microbiol.* **2010**, *8*, 272–280. [[CrossRef](#)] [[PubMed](#)]
3. Rohmer, M.; Knani, M.; Simonin, P.; Sutter, B.; Sahm, H. Isoprenoid biosynthesis in bacteria: A novel pathway for the early steps leading to isopentenyl diphosphate. *Biochem. J.* **1993**, *295*, 517–524. [[CrossRef](#)] [[PubMed](#)]
4. Rodriguez-Concepcion, M. The MEP Pathway: A New Target for the Development of Herbicides, Antibiotics and Antimalarial Drugs. *Curr. Pharm. Des.* **2004**, *10*, 2391–2400. [[CrossRef](#)] [[PubMed](#)]
5. Rohdich, F.; Bacher, A.; Eisenreich, W. Isoprenoid biosynthetic pathways as anti-infective drug targets. *Biochem. Soc. Trans.* **2005**, *33*, 785–791. [[CrossRef](#)] [[PubMed](#)]
6. McFadden, G.I. The apicoplast. *Protoplasma* **2011**, *248*, 641–650. [[CrossRef](#)] [[PubMed](#)]
7. Ralph, S.A.; D’Ombrain, M.C.; McFadden, G.I. The apicoplast as an antimalarial drug target. *Drug Resist. Updates* **2001**, *4*, 145–151. [[CrossRef](#)] [[PubMed](#)]
8. Sato, S. The apicomplexan plastid and its evolution. *Cell. Mol. Life Sci.* **2011**, *68*, 1285–1296. [[CrossRef](#)]
9. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H.K.; et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. *Science* **1999**, *285*, 1573–1576. [[CrossRef](#)]
10. Okuhara, M.; Kuroda, Y.; Goto, T.; Okamoto, M.; Terano, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. Studies on new phosphonic acid antibiotics. III. Isolation and characterization of FR-31564, FR-32863 and FR-33289. *J. Antibiot. (Tokyo)* **1980**, *33*, 24–28. [[CrossRef](#)]
11. Kuroda, Y.; Okuhara, M.; Goto, T.; Okamoto, M.; Terano, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. Studies on new phosphonic acid antibiotics. IV. Structure determination of FR-33289, FR-31564 and FR-32863. *J. Antibiot. (Tokyo)* **1980**, *33*, 29–35. [[CrossRef](#)]
12. Hirsch, A.K.; Fischer, F.R.; Diederich, F. Phosphate recognition in structural biology. *Angew. Chem. Int. Ed. Engl.* **2007**, *46*, 338–352. [[CrossRef](#)] [[PubMed](#)]
13. Wiesner, J.; Borrmann, S.; Jomaa, H. Fosmidomycin for the treatment of malaria. *Parasitol. Res.* **2003**, *90*, S71–S76. [[CrossRef](#)] [[PubMed](#)]
14. Mine, Y.; Kamimura, T.; Nonoyama, S.; Nishida, M.; Goto, S.; Kuwahara, S. In vitro and in vivo antibacterial activities of FR-31564, a new phosphonic acid antibiotic. *J. Antibiot. (Tokyo)* **1980**, *33*, 36–43. [[CrossRef](#)]
15. Kurz, T.; Geffken, D.; Kaula, U. Organophosphoric Compounds and Use Thereof. Patent WO2005048715-A2, 2 June 2005.
16. Kurz, T.; Schlüter, K.; Kaula, U.; Bergmann, B.; Walter, R.D.; Geffken, D. Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of Fosmidomycin and FR900098. *Bioorg. Med. Chem.* **2006**, *14*, 5121–5135. [[CrossRef](#)] [[PubMed](#)]
17. Haemers, T.; Wiesner, J.; Van Poecke, S.; Goeman, J.; Henschker, D.; Beck, E.; Jomaa, H.; Van Calenbergh, S. Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1888–1891. [[CrossRef](#)]
18. Schlüter, K.; Walter, R.D.; Bergmann, B.; Kurz, T. Arylmethyl substituted derivatives of Fosmidomycin: Synthesis and antimalarial activity. *Eur. J. Med. Chem.* **2006**, *41*, 1385–1397. [[CrossRef](#)]
19. Verbrugghen, T.; Cos, P.; Maes, L.; Van Calenbergh, S. Synthesis and Evaluation of α -Halogenated Analogues of 3-(Acetylhydroxyamino)propylphosphonic Acid (FR900098) as Antimalarials. *J. Med. Chem.* **2010**, *53*, 5342–5346. [[CrossRef](#)]
20. Behrendt, C.T.; Kunfermann, A.; Illarionova, V.; Matheussen, A.; Pein, M.K.; Gräwert, T.; Kaiser, J.; Bacher, A.; Eisenreich, W.; Illarionov, B.; et al. Reverse Fosmidomycin Derivatives against the Antimalarial Drug Target IspC (Dxr). *J. Med. Chem.* **2011**, *54*, 6796–6802. [[CrossRef](#)]
21. Woo, Y.H.; Fernandes, R.P.; Proteau, P.J. Evaluation of fosmidomycin analogs as inhibitors of the *Synechocystis* sp. PCC6803 1-deoxy-D-xylulose 5-phosphate reductoisomerase. *Bioorg. Med. Chem.* **2006**, *14*, 2375–2385. [[CrossRef](#)]

22. San Jose, G.; Jackson, E.R.; Haymond, A.; Johnny, C.; Edwards, R.L.; Wang, X.; Brothers, R.C.; Edelstein, E.K.; Odom, A.R.; Boshoff, H.I.; et al. Structure–Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from *Mycobacterium tuberculosis* and *Yersinia pestis*. *ACS Infect. Dis.* **2016**, *2*, 923–935. [[CrossRef](#)]
23. Fokin, A.A.; Yurchenko, A.G.; Rodionov, V.N.; Gunchenko, P.A.; Yurchenko, R.I.; Reichenberg, A.; Wiesner, J.; Hintz, M.; Jomaa, H.; Schreiner, P.R. Synthesis of the Antimalarial Drug FR900098 Utilizing the Nitroso-Ene Reaction. *Org. Lett.* **2007**, *9*, 4379–4382. [[CrossRef](#)] [[PubMed](#)]
24. Perruchon, J.; Ortmann, R.; Schlitzer, M. A Novel Short and Efficient Synthetic Route to the Antimalarial Agent FR900098 and Derivatives. *Synthesis* **2007**, *2007*, 3553–3557.
25. Courtens, C.; Risseuw, M.; Caljon, G.; Cos, P.; Van Calenbergh, S. Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents. *ACS Med. Chem. Lett.* **2018**, *9*, 986–989. [[CrossRef](#)] [[PubMed](#)]
26. Masini, T.; Hirsch, A.K.H. Development of Inhibitors of the 2C-Methyl-d-erythritol 4-Phosphate (MEP) Pathway Enzymes as Potential Anti-Infective Agents. *J. Med. Chem.* **2014**, *57*, 9740–9763. [[CrossRef](#)] [[PubMed](#)]
27. San Jose, G.; Jackson, E.R.; Uh, E.; Johnny, C.; Haymond, A.; Lundberg, L.; Pinkham, C.; Kehn-Hall, K.; Boshoff, H.I.; Couch, R.D.; et al. Design of potential bisubstrate inhibitors against *Mycobacterium tuberculosis* (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr)-Evidence of a novel binding mode. *Med. Chem. Comm.* **2013**, *4*, 1099–1104. [[CrossRef](#)]
28. Nguyen-Trung, A.T.; Tritsch, D.; Grosdemange-Billiard, C.; Rohmer, M. Synthesis of tetrazole analogues of phosphonohydroxamic acids: An attempt to improve the inhibitory activity against the DXR. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1643–1647. [[CrossRef](#)]
29. Edwards, R.L.; Brothers, R.C.; Wang, X.; Maron, M.I.; Ziniel, P.D.; Tsang, P.S.; Kraft, T.E.; Hruz, P.W.; Williamson, K.C.; Dowd, C.S.; et al. MEPicides: Potent antimalarial prodrugs targeting isoprenoid biosynthesis. *Sci. Rep.* **2017**, *7*, 8400. [[CrossRef](#)]
30. McKenney, E.S.; Sargent, M.; Khan, H.; Uh, E.; Jackson, E.R.; San Jose, G.; Couch, R.D.; Dowd, C.S.; van Hoek, M.L. Lipophilic prodrugs of FR900098 are antimicrobial against *Francisella novicida* in vivo and in vitro and show GlpT independent efficacy. *PLoS ONE* **2012**, *7*, e38167. [[CrossRef](#)]
31. Magoulas, G.E.; Tsigkou, T.; Skondra, L.; Lamprou, M.; Tsoukala, P.; Kokkinogouli, V.; Pantazaka, E.; Papaioannou, D.; Athanassopoulos, C.M.; Papadimitriou, E. Synthesis of novel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents. *Bioorg. Med. Chem.* **2017**, *25*, 3756–3767. [[CrossRef](#)]
32. Capci, A.; Lorion, M.M.; Wang, H.; Simon, N.; Leidenberger, M.; Borges Silva, M.C.; Moreira, D.R.M.; Zhu, Y.; Meng, Y.; Chen, J.Y.; et al. Artemisinin-(Iso)quinoline Hybrids by C-H Activation and Click Chemistry: Combating Multidrug-Resistant Malaria. *Angew. Chem. Int. Ed. Engl.* **2019**, *58*, 13066–13079. [[CrossRef](#)]
33. Sinha, M.; Dola, V.R.; Agarwal, P.; Srivastava, K.; Haq, W.; Puri, S.K.; Katti, S.B. Antiplasmodial activity of new 4-aminoquinoline derivatives against chloroquine resistant strain. *Bioorg. Med. Chem.* **2014**, *22*, 3573–3586. [[CrossRef](#)] [[PubMed](#)]
34. Miller, M.J.; Walz, A.J.; Zhu, H.; Wu, C.; Moraski, G.; Möllmann, U.; Tristani, E.M.; Crumbliss, A.L.; Ferdig, M.T.; Checkley, L.; et al. Design, Synthesis, and Study of a Mycobactin–Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and Malaria. *J. Am. Chem. Soc.* **2011**, *133*, 2076–2079. [[CrossRef](#)] [[PubMed](#)]
35. Pepe, D.A.; Toumpa, D.; Andre-Barres, C.; Menendez, C.; Mouray, E.; Baltas, M.; Grellier, P.; Papaioannou, D.; Athanassopoulos, C.M. Synthesis of Novel G Factor or Chloroquine–Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity. *ACS Med. Chem. Lett.* **2020**, *11*, 921–927. [[CrossRef](#)] [[PubMed](#)]
36. Suresh, S.; Shyamraj, D.; Larhed, M. Synthesis of antimalarial compounds fosmidomycin and FR900098 through N- or P-alkylation reactions. *Tetrahedron* **2013**, *69*, 1183–1188. [[CrossRef](#)]
37. Uh, E.; Jackson, E.R.; San Jose, G.; Maddox, M.; Lee, R.E.; Lee, R.E.; Boshoff, H.I.; Dowd, C.S. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 6973–6976. [[CrossRef](#)]
38. Ruiz, J.; Azema, J.; Payrastré, C.; Baltas, M.; Tuccio, B.; Vial, H.; Andre-Barres, C. Antimalarial bicyclic peroxides belonging to the G-factor family: Mechanistic aspects of their formation and iron (II) induced reduction. *Curr. Top. Med. Chem.* **2014**, *14*, 1668–1683. [[CrossRef](#)]

39. Stoica, S.; Magoulas, G.E.; Antoniou, A.I.; Suleiman, S.; Cassar, A.; Gatt, L.; Papaioannou, D.; Athanassopoulos, C.M.; Schembri-Wismayer, P. Synthesis of minoxidil conjugates and their evaluation as HL-60 differentiation agents. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1145–1150. [[CrossRef](#)]
40. Kumar, M.; Singh, K.; Ngwane, A.H.; Hamzabegovic, F.; Abate, G.; Baker, B.; Wiid, I.; Hoft, D.F.; Ruminski, P.; Chibale, K. Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis. *Bioorg. Med. Chem.* **2018**, *26*, 833–844. [[CrossRef](#)]
41. Zhao, C.; Jiang, Z.; Mu, R.; Li, Y. A novel sensor for dopamine based on the turn-on fluorescence of Fe-MIL-88 metal-organic frameworks-hydrogen peroxide-o-phenylenediamine system. *Talanta* **2016**, *159*, 365–370. [[CrossRef](#)]
42. Marozienne, A.; Lesanavicius, M.; Davioud-Charvet, E.; Aliverti, A.; Grellier, P.; Sarlauskas, J.; Cenas, N. Antiplasmodial Activity of Nitroaromatic Compounds: Correlation with Their Reduction Potential and Inhibitory Action on Plasmodium falciparum Glutathione Reductase. *Molecules* **2019**, *24*, 4509. [[CrossRef](#)]
43. Mwande Mague, G.; Lekana-Douki, J.-B.; Mouray, E.; Bousquet, T.; Grellier, P.; Pellegrini, S.; Toure Ndouo, F.S.; Lebibi, J.; Pélineski, L. Synthesis and in vitro antiplasmodial activity of ferrocenyl aminoquinoline derivatives. *Eur. J. Med. Chem.* **2015**, *90*, 519–525. [[CrossRef](#)]
44. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**, *7*, 42717. [[CrossRef](#)] [[PubMed](#)]
45. Trager, W.; Jensen, J. Human malaria parasites in continuous culture. *Science* **1976**, *193*, 673–675. [[CrossRef](#)]

Sample Availability: Samples of the compounds are available from the authors.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).